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Summary 
 
This thesis reports the cloning, overexpression and characterization of two interesting 
proteins from Helicobacter pylori: Heat Shock protein A (HspA), and CoaX (Type III 
Pantothenate kinase). Helicobacter pylori  is a gram negative bacterium that colonises 
the human stomach. It is present in more than half of the world’s population and causes 
major diseases such as gastritis, peptic ulcers and stomach cancer.  
The current treatment against H. pylori, consisting of a combination of a proton pump 
inhibitor and two different antibiotics, is effective but has several drawbacks such as 
increased risk of antibiotic resistance and no protection against re-infection. Although 
extensive research is going on to develop a vaccine that would be an attractive 
alternative or a complement to the current treatment, there is no vaccine available 
against H. pylori today.  
Helicobacter pylori produces an unusual GroES homologue protein referred as to HspA 
(Heat-shock protein A). Besides its classical co-chaperone activity, HspA plays 
additional roles being involved in nickel binding. It also exhibits an extended subcellular 
localization, ranging from cytoplasm to bacterial cell surface. In fact, unlike its  
homologue proteins, HspA is highly immunogenic being also present in the extra cellular 
media. For this reason it is considered a target for new therapeutic strategies. HspA 
consists of two domains: an N-terminal domain (domain A, residues 1-90), that is 
homologous with other GroES bacterial proteins and a C-terminal domain (domain B, 
residues 91-118), which other GroES-like proteins lack. Domain B is unique to HspA 
and contains 8 histidines and 4 cysteines which have been suggested to be involved in 
nickel binding. 
This study points on a unique characteristic of HspA among all GroES proteins: a high 
content of cysteine residues. Cysteine is the less represented residue in all known 
GroES proteins examined. In this context we have produced and characterized a 
recombinant HspA and its mutants Cys94Ala and Cys94Ala/Cys111Ala and we have 
identified the disulphide bridge pattern of the protein. In particular the study has been 
addressed on the Cys oxidised/reduced state; the disulphide bridge pattern has been 
assigned by integrating classical biochemical methodologies with mass spectrometry. 
We found that the cysteines (two from domain A and four from domain B) are engaged 
in three disulphide bonds between residues Cys51/Cys53, Cys94/Cys111 and 
Cys95/Cys112. Our results suggest that two of the disulphide bridges, located in the B 
domain, force the C-terminal domain to adopt a unique closed loop structure that would 
be optimal for binding to 2 Ni ions as suggested by the different redox environments that 
the protein experiences inside and outside the bacterial cell.  
H.pylori also produces a new Pantothenate Kinase isoform (HpCoaX) encoded by the 
CoaX gene referred as to HP0862, involved in a critical pathway for pathogen survival: 
that of coenzyme A (CoA) biosynthesis. In particular, pantothenate kinase catalyzes the 
first step of the universal five-step CoA biosynthetic pathway. HpCoaX enzyme, 
belonging to the type III class, differs in sequence, structure and enzymatic properties 
from the previously characterized type I, found essentially in bacteria, and type II forms 
found in eukarya as well as in some bacteria; its activity is not regulated by CoA and 
thio-esters. In this context we have cloned the HpCoaX gene in pRoEX-HTc vector and 
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expressed the recombinant protein in  E.coli BL21( DE3) cells. We have optimized the 
experimental conditions for purification and stability of the expressed protein. The 
purified HpCoax was analyzed by gel filtration chromatography and dynamic light 
scattering to investigate its state of oligomerization. Results show that HpCoaX exists as 
a homodimer, as predicted by its homology with the other PanK III bacterial proteins. 
The purified protein was also characterized by mass spectrometry assay. Crystallization 
trials using a nanodispensator were also carried out in order to obtain crystals suitable 
for an X-ray diffraction analysis.  
H. pylori infections remain a significant global public health problem. Vaccine and 
antagonist compound development against this infection appears to be a preferable 
strategy. Actually there is a substantial requirement for new drug targets as alternative 
strategies for the treatment of H. pylori infections, since there is often resistance against 
traditional antibiotic therapy. Comparison of substrate binding and catalytic sites of 
PanK-III with those of PanK-II and PanK-I type, reveals drastic differences in the binding 
modes for both ATP and pantothenate substrates, suggesting that these differences 
may be exploited in the development of new inhibitors targeting specifically PanK-III 
type. HpCoaX inhibitors may be  a good goal, interfering with the survival mechanism of  
H. pylori within the gastric mucosa. For the all above reasons, both HpCoaX and HspA 
can be considered to be a good targets for new therapeutic strategies. Our study 
belongs to a wide research line with the aim of identifying, characterizing and clarifying 
the role of specific targets, in particular of multifunctional uncharacterized proteins 
involved in critical pathway for the pathogen survival. 
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Riassunto 
Lo scopo del seguente progetto di dottorato ha riguardato lo studio sperimentale di 
alcune proteine con caratteristiche multifunzionali del patogeno gram-negativo 
Helicobacter pylori. Il recente sviluppo delle metodiche d’interazione molecolare su larga 
scala, basate sia su sistemi  in vitro che in vivo ha permesso di evidenziare le mappe 
d’interazione proteina-proteina relative ad un intero organismo; tali interazioni risultano 
coinvolte in molteplici processi biologici cellulari. Di particolare interesse risultano quelle 
mappe d’interazione di organismi altamente patogeni per l’uomo come Helicobacter 
pylori [Ito, T., et al. 2001], [Rain G.C., et al. 2001]. Helicobacter pylori è il principale 
agente causale dell’infiammazione cronica della mucosa gastrica e dell’ulcera peptica, e 
rappresenta uno dei principali fattori di rischio per la neoplasia di tipo gastrico 
[McGowan C.C., et al. 1996], [Parsonnet J., et al 1994]. Per colonizzare il 
microambiente acido dell’epitelio gastrico il batterio ha sviluppato delle efficaci strategie 
di adattamento e colonizzazione.  Infatti H. pylori è in grado di produrre un elevato 
assortimento di fattori di virulenza capaci di neutralizzare il pH della mucosa gastrica e 
quindi di sopravvivere nell’ambiente estremamente acido dello stomaco.  
Pertanto lo studio delle proteine coinvolte nell’ omeostasi e nella regolazione metallo-
dipendente,  così come quello relativo alla caratterizzazione dei componenti proteici 
coinvolti nei principali pathway biosintetici, riveste primaria importanza nel campo delle 
infezioni ospite-patogeno, poiché la limitazione di metalli è associata all’induzione 
dell’espressione dei geni di virulenza in molti patogeni batterici.  L’obiettivo principale 
dell’ intero progetto di ricerca di dottorato è la caratterizzazione biochimica e strutturale 
di alcune proteine multifunzionali del patogeno gram-negativo H. pylori, il cui genoma 
risulta essere accuratamente annotato in seguito al completo sequenziamento [Tomb 
G.C., et al. 1997].  L’accessibilità di tale genoma sequenziato ha avuto un profondo 
impatto su tutti gli aspetti di ricerca che vanno dalle basi biologiche di H. pylori 
all’identificazione di specifici target fino allo sviluppo di nuove strategie terapeutiche 
volte al controllo e infine alla completa eradicazione di questo importante agente 
patogeno.  
Il potenziale interesse biotecnologico del progetto risiede nella individuazione e 
caratterizzazione  di nuovi target coinvolti nel meccanismo di adattamento e 
sopravvivenza del patogeno H. pylori  e  indispensabili per il suo metabolismo, allo 
scopo di effettuare una progettazione razionale di potenziali farmaci (drug design). Le 
proteine selezionate come oggetto del mio studio sono Heat schok protein A (HspA) e la 
pantotenato kinasi di tipo III (HpCoaX). In particolare l’HspA essendo una componente 
del patogeno con caratteristiche immunogeniche rappresenta un target favorito per lo 
sviluppo di un vaccino. Ciò rappresenterebbe una valida alternativa terapeutica al 
tradizionale cocktail antibiotico previsto per eradicare l’Helicobacter e che purtroppo 
spesso risulta fallimentare. [Choudhry A. E., et al. 2003]  
Nell’ambito di questo progetto ci si è avvalsi di metodiche che sfruttano un approccio 
interdisciplinare integrando discipline biologiche, biotecnologiche, chimiche e 
biochimiche allo scopo di affrontare problematiche di natura biotecnologica sia base che 
applicative. In particolare le principali strategie sono basate sull’ utilizzo di metodiche di 
biologia molecolare, come metodiche di clonaggio ed espressione eterologa di proteine 
ricombinanti, utilizzando specifici vettori di espressione e ceppi modificati di E. coli, 
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tecniche biochimiche per la purificazione delle proteine (Cromatografia per affinità, 
cromatografia per esclusione molecolare e light scattering dinamico) integrate con 
indagini di spettrometria di massa e di tipo strutturale (cristallizzazione di proteine).  
Dapprima l’attenzione è stata rivolta prevalentemente allo studio della Heat Shock 
protein A (HspA) espressa in condizioni di stress cellulare, e coinvolta nell’ omeostasi 
del Nickel [Kansau I., et al. 1996], [Ng E.K., et al. 1999]. Il nickel è un elemento 
essenziale per il metabolismo anaerobico dei microrganismi, incluso il patogeno gram-
negativo H. pylori. L’omeostasi di questo metallo è richiesta per preservare l’equilibrio 
tra i livelli di Nickel accessibili per le funzioni cellulari batteriche ed i potenziali effetti 
derivanti da un eccessivo accumulo intracellulare del metallo stesso. Si tratta di un 
complesso processo che coinvolge l’uptake, l’utilizzazione, l’efflusso ed il deposito degli 
ioni nickel e che risulta regolato a differenti livelli. Pertanto risultano fortemente attivi 
all’interno del patogeno quei sistemi deputati alla regolazione dei livelli intracellulari di 
Ni2+ e alla sua detossificazione;  H. pylori  esprime  molteplici  proteine che risultano 
coinvolte nell’omeostasi di questo metallo [Robert J. Maier, et al. 2007] ed una serie di 
proteine accessorie tra cui si annovera la Heat Shock protein A (HspA) o HP0011, che 
contiene 6 cisteine impegnate in 3 ponti disolfurici. Lo studio ha condotto 
alll’assegnazione del corretto pattern di formazione dei ponti disolfurici ed in particolare 
è stato delucidato il ruolo svolto da due  ponti disolfurici vicinali presenti nel dominio B,  
rilevante per la funzione Ni-dipendente di HspA in H. pylori. HspA è una proteina, 
abbondante in H. pylori, conosciuta essere immunogenica. Inaspettatamente presenta 
una doppia localizzazione: infatti questa proteina citoplasmatica può essere rilevata 
anche sulla superficie del batterio, attraverso un meccanismo di secrezione ancora non 
identificato oppure presumibilmente mediante un processo di autolisi programmata 
[Vanet, et al. 1998]. Essa rappresenta un inusuale omologo appartenente alla classe 
delle GroES, e consta di due regioni: il dominio A (omologo con le altre proteine GroES 
batteriche)  ed il dominio B ricco in cisteine ed istidine. La presenza di tale dominio 
risulta essere unica e peculiare per Helicobacter pylori ed Helicobacter acinonuchis e 
gioca un ruolo essenziale nel recupero e nel rilascio del nickel [Sun X., et al. 2008], 
[Suerbaum S., et al. 1994]. L’ interesse è stato focalizzato sullo studio di una 
caratteristica peculiare esibita dall’ HspA  nell’ambito di tutte le proteine GroES fin’ora 
conosciute: un elevato contenuto di residui cisteinici. Viceversa, da analisi effettuate 
mediante tools bioinformatici, la cisteina risulta essere proprio l’aminoacido meno 
rappresentato all’interno della classe delle proteine GroES. La presenza del dominio B  
fornisce quindi un ruolo aggiuntivo all’HspA indipendente dalla classica attività di co-
chaperone: tale ruolo potrebbe essere mediato da questo elevato contenuto di residui 
cisteinici, con modalità  redox-dipendente.  Al fine di indagare sul ruolo giocato da tali 
residui cisteinici, sono stati prodotti per via ricombinante sia la proteina HspA wild-type 
che due mutanti a livello di due residui cisteinici nel dominio B: Cys94Ala e 
Cys94Ala/Cys111Ala. Attraverso la combinanzione sia di metodiche biochimiche, che di 
spettrometria di massa, è stato determinato lo stato di ossidazione per i residui cisteinici, 
assegnato il corretto pattern dei ponti disolfurici, in virtù dei quali è stato possibile 
mettere in evidenza una struttura unica per l’HspA a livello del dominio B. Da questo 
studio è stato evidenziato che HspA contiene tre ponti disolfurici intramolecolari. I ponti 
coinvolgono sia il dominio A (Cys51–Cys53) che il dominio B legante il  nickel (Cys94–
Cys111 e Cys95–Cys112). Ed è proprio in quest’ultimo dominio che il piccolo anello che 
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si viene a creare tra le quattro Cys rappresenta un forte determinante strutturale fin’ora 
osservato unicamente per una conotoxina, un piccolo peptide (pdb code 1wct). Per cui 
in HspA la presenza dei due consecutivi ponti disolfurici, forza la topologia del C-
terminale della proteina generando una struttura ‘‘lasso-like’’ descritta per la prima volta. 
Questa struttura potrebbe fornire la conformazione ideale al dominio B per legare gli ioni 
nickel. Il ruolo di legare il Nickel, potrebbe essere svolto dall’HspA attraverso il 
sequestro del Ni sia intracellulare che di quello extracellulare, in virtù della presenza 
della proteina sia a livello subcellulare che all’esterno della membrana batterica. Su 
questa linea è possibile speculare che la funzione di legare il Nickel potrebbe essere 
modulata dal differente stato ridotto/ossidato dei residui cisteinici: sulla superficie 
batterica dove l’ambiente è tipicamente ossidativi la proteina esibisce il pattern dei ponti 
S-S, mentre nel citoplasma i ponti disolfurici possono esibire una differente stabilità 
dipendente dalle condizioni quali pH e deplezione del Nickel. In conclusione essendo le 
cisteine fortemente conservate nei differenti ceppi batterici di H. pylori, esse potrebbero 
assistere il legame/rilascio degli ioni nickel. Pertanto la presenza della peculiare 
struttura generata dai due ponti disolfurici vicinali nel dominio B è rilevante per la 
funzione Ni-dipendente di HspA in H. pylori [Loguercio S., et al. 2008]. 
In proseguimento di tali studi, sono stati condotti degli esperimenti  in presenza di metalli 
quali il Nickel e il Bismuto, per i quali l’ HspA presenta una notevole affinità di legame 
[Cun, et al. 2008]. Si è ipotizzato che la presenza del metallo possa indurre il dominio B 
dell’HspA a strutturarsi in un  folding adatto a legare il metallo. In pratica, dopo 
opportuna riduzione dei ponti disolfurici (mediante TCEP),  e successiva incubazione  
della proteina con i suddetti metalli, è stato valutato il comportamento della proteina. In 
seguito all’incubazione in presenza dei due metalli i campioni sono stati sottoposti a 
esperimenti di cromatografia per esclusione molecolare (Gel filtrazione) per paragonare 
il differente comportamento della proteina in assenza dei due metalli e senza effetti da 
parte di un agente riducente, già condotti precedentemente. La proteina così trattata, in 
entrambe le varianti (in presenza ed in assenza dello ione Nickel e del bismuto) è stata 
sottoposta ad uno screening di cristallizzazione utilizzando svariati kit a disposizione e 
mediante l’utilizzo del Nanodispensatore. Sfortunatamente, sia l’HspA-Ni+2 che l’HspA-
Bi+3 non hanno mai formato cristalli evidenziando  una intrinseca difficoltà nella 
cristallizzazione di questa proteina. 
Successivamente l’attenzione  è stata incentrata sul secondo target proteico oggetto di 
studio nell’ambito del programma di dottorato. Si tratta di una pantotenato chinasi 
(PanK) che partecipa al primo di cinque step della via biosintetica che porta alla 
produzione del coenzima A, un cofattore indispensabile in tutte le forme di vita [Begley 
T.P., et al. 2001]. Il Coenzima A (CoA) rappresenta un cofattore essenziale in tutti i 
sistemi biologici, in quanto funge da principale fonte di gruppi acili. Inoltre è stato 
dimostrato che il CoA gioca un ruolo chiave nell’omeostasi dello stato redox 
provvedendo ad un’ importante difesa antiossidante, per un elevato numero di patogeni  
batterici che, differentemente da E. coli sono privi del meccanismo GSH-dipendente. La 
Pantotenato chinasi (PanK) è un enzima ampiamente conservato nelle differenti specie 
batteriche (da E. coli a B. subtilis): catalizza la fosforilazione ATP-dipendente del 
Pantotenato (vitamina B5, Pan) con formazione del 4’-fosfopantotenato e svolge un ruolo 
chiave nella regolazione della biosintesi del CoA. In E. coli è stato dimostrato essere 
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presente in forma omodimerica ed essere regolato nell’ attività da feedback negativo a 
carico del prodotto metabolico. Nonostante l’intero pathway biosintetico del CoA, risulti 
abbastanza conservato nelle diverse specie batteriche, soltanto alcuni degli enzimi che 
in E. coli convertono il Pan in CoA, risultano conservate in determinati patogeni; infatti  è 
stato identificato recentemente, un nuovo tipo di PanK, codificata dal gene CoaX, e che 
catalizza il primo step della via biosintetica del CoA in  patogeni come B. anthracis e H. 
pylori. Questa nuova isoforma, denominata Pank III, appartiene alla classe delle chinasi 
del gruppo 4 (famiglia delle Ribonucleasi H-like) ed esibisce distinte caratteristiche 
biochimiche rispetto alla classe I e II: in particolare non risente dell’ inibizione da 
feedback negativo ad opera del CoA stesso e suoi tioesteri; non mostra  interazione  
con analoghi del substrato (Pan antimetaboliti); esibisce inoltre caratteristiche cinetiche 
uniche in quanto possiede bassa specificità per il legame all’ ATP [Leisl A., et al. 2005], 
[Hong B.S., et al. 2006]. Della pantotenato chinasi da Helicobacter pylori, si hanno a 
disposizione poche conoscenze, data la scarsità di dati in letteratura. Obiettivo 
dell’attività di ricerca del II anno è stato quello di produrre e caratterizzare la proteina 
PankIII da H. pylori (HpCoaX). Sulla base di analisi statistiche (condotte mediante il tool 
bioinformatico SEED) è stato possibile confrontare la classe delle PanK I e II con la 
classe III, e selezionare gli organismi patogeni, in cui l’attività pantotenica risulta 
esercitata esclusivamente dai prodotti del gene CoaX, tra cui H. pylori. Da tale analisi 
derivano importanti implicazioni quali il miglioramento della comprensione dei 
meccanismi che stanno alla base dell’evoluzione convergente degli enzimi chiave, 
coinvolti in pathway metabolici essenziali (come la biosintesi del CoA), nonchè  
l’identificazione di nuovi target terapeutici: queste PanKs III, esibendo infatti distinte 
caratteristiche, potrebbero rappresentare dei candidati ideali. Attraverso l’ applicazione 
delle principali tecniche di biologia molecolare, Il gene HpCoaX è stato clonato con 
successo nel vettore di espressione appartenente alla classe pPROEX-HT. Il plasmide 
di espressione recante la proteina di fusione con l’His6 –tag all’N-terminale è stato 
trasformato nel ceppo di espressione competente E. coli BL21(DE3)pLysS. Nel secondo 
anno di attività la proteina è stata così prodotta su larga scala per per via ricombinante 
ed usata per tutte le caratterizzazioni successive. Analizzando la sequenza 
amminoacidica della HpCoaX è possibile individuare 8 residui cisteinici che non 
risultano impegnati nella formazione di alcun ponte disolfurico intramolecolare. Tale dato 
è stato predetto e successivamente confermato da analisi di spettrometria di massa 
effettuate dopo il saggio della Vinilpiridina, con denaturazione e successiva alchilazione 
delle Cys presenti nel campione, in assenza di agenti riducenti. La presenza delle 8 Cys 
libere comporta la formazione di ponti disolfurici non nativi tra le varie subunità 
monomeriche con conseguente formazione di diversi stati oligomerici del campione.  
Questi vengono individuati come un pattern elettroforetico multiplo, con bande a più alto 
peso molecolare, quando l’ analisi SDS-PAGE, è condotta in assenza di β-
mercaptoetanolo. Al fine di ottenere una preparazione stabile della proteina, tutti i 
passaggi di purificazione, dialisi e concentrazione sono stati eseguiti in presenza di 2-3 
mM DTT, e per limitare l’ossidazione aerobica dell’agente riducente, il campione è stato 
sottoposto a flusso di N2, in tutti gli steps. Allo scopo di valutare lo stato di 
oligomerizzazione di Hp_0862, la proteina è stata dapprima analizzata mediante 
cromatografia per gel filtrazione. La Pank III da H. pylori mostra un volume di eluizione 
caratteristico di una proteina di circa 50 kDa (Ve = 15.2 ml/min) e che rappresenta uno 
stato omodimerico, come risulta dalla predizione per omologia. Il dato è stato 
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confermato mediante un’analisi molto più accurata di DLS (light scattering dinamico) 
effettuata sul campione eluito dalla gel filtrazione. La proteina cosi trattata è stata 
sottoposta ad uno screening di cristallizzazione utilizzando svariati kit di agenti 
precipitanti, a diverse temperature (20°C e 4°C), avvalendosi del robot 
Nanodispensatore Hamilton STARLET disponibile presso il nostro dipartimento. Sono 
state successivamente condotte analisi al fine di ottimizzare mediante la costruzione di 
una matrice, le condizioni ideali per la cristallizzazione su larga scala: le condizioni di 
temperatura a 4°C sono risultate essere la condizione essenziale al fine di formare, 
riprodurre e stabilizzare i cristalli di HpCoaX. La condizione di reservoir di riferimento su 
cui ci si è basati per riprodurre e sviluppare i cristalli è quella proveniente dal Kit INDEX 
2 e corrispondente alla seguente composizione di agente precipitante: 0.1 M Bis-Tris pH 
6.5, 0.2 M solfato di ammonio, PEG 400. Su tale condizione si è effettuata la 
costruzione della matrice di cristallizzazione, variando le concentrazioni e mantenendo 
costante il valore di pH. I cristallini cosi ottenuti, caratterizzati da forma geometrica 
regolare, ed opportunamente conservati a 4°C sono stati dapprima testati su SDS-
PAGE al fine di valutare l’ effettiva formazione di cristalli della proteina di interesse; 
confermato ciò sono stati di seguito sottoposti a delle analisi preliminari mediante 
diffrazione ai raggi X. Purtroppo l’elevato disordine all’interno del cristallo e la loro 
scarsa stabilità, hanno consentito di registrare solo deboli pattern di diffrazione a 5 Å di 
risoluzione. Nonostante i molteplici esperimenti per migliorare la qualità dei cristalli 
questi non hanno mai prodotto un pattern di diffrazione ad alta-media risoluzione che ci 
permettesse di proseguire in tal senso e indirizzare le seguenti analisi verso una 
risoluzione della struttura tridimensionale. A questo punto sono stati effettuati prove di 
co-cristallizzazione mediante l’utilizzo sia del substrato (PAN), che del catalizzatore 
della reazione, un analogo non idrolizzabile dell’ATP (AMPPNP), al fine di ottenere dei 
cristalli ad elevato potere diffrangente. Nonostante l’aggiunta di tali composti, sia 
direttamente nella goccia contenete i cristalli di HpCoaX (soaking), che in nuove prove 
di cristallizzazione in cui i composti venivano miscelati in nuove gocce contenenti la 
soluzione di proteina, non è stato riscontrato nessun miglioramento nella qualità dei 
cristalli. 
Il potenziale interesse biotecnologico del progetto risiede nell’ aver individuato e 
caratterizzato, nuovi target coinvolti nel meccanismo di adattamento e sopravvivenza 
del patogeno H. pylori ed indispensabili e vitali per il suo metabolismo. Le proteine 
oggetto del mio studio rappresentano infatti delle molecole di notevole interesse. In 
particolare la HpCoaX e l’ HspA essendo enzimi chiave nel metabolismo del patogeno 
risultano dei bersagli adatti per la costruzione di specifici inibitori: ciò rappresenterebbe 
una valida alternativa terapeutica al tradizionale cocktail antibiotico previsto per le 
infezioni da Helicobacter e che purtroppo spesso non rappresenta un trattamento 
definitivo per la comparsa di casi di recidiva. Dato l’elevato grado di variabilità a livello 
del genoma del patogeno, infatti, risulta elevato anche il grado di resistenza verso 
moltissimi antibiotici. Inoltre si pensa che in Helicobacter pylori (così come in molti altri 
organismi patogeni) sia la PanK ad essere responsabile del meccanismo di sviluppo 
della resistenza a diversi antibiotici. Per cui potrebbe essere interessante sviluppare dei 
potenziali inibitori della PanK III di H. pylori, oppure nuovi composti antimicrobici con 
modalità d’azione alternativa [Choudhry A. E., et al. 2003]. 
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Mediante approcci molecolari, biochimici, spettroscopici sono stati chiariti alcuni 
meccanismi che governano la funzione delle proteine coinvolte nell’omeostasi redox e 
nel metabolismo batterico e costituiranno sia la base per lo sviluppo di nuovi farmaci per 
il blocco dell’infezione, sia la base per lo sviluppo di possibili vaccini. Ci si attende, 
pertanto, che i risultati ottenuti avranno a lungo termine un elevato impatto nel campo 
biotecnologico e biomedico, dal momento che le patologie da H. pylori colpiscono circa il 
50% della popolazione mondiale. 
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Chapter I: 
General Introduction 
 
1.1 History 
For a long time, the human stomach was considered to be a sterile organ where no 
microorganisms could live due to the harsh acidic conditions. This view changed in 
1982, when Warren and Marshall were able to culture Helicobacter pylori bacteria from 
gastric biopsies, and found that the bacteria (previously designated Vibrio rugula and 
Campylobacter pylori) were present in patients with active chronic gastritis, duodenal 
ulcer or gastric ulcer. They were later awarded the Nobel Prize for physiology and 
medicine (in 2005) for their important discovery of H. pylori and its role in gastritis and 
peptic ulcer disease. The possibility that peptic ulcers could be caused by a bacterium, 
and not by stress, spicy food or other factors was a surprise to the scientific community, 
and it was difficult for Warren and Marshall to change the prevailing dogma. To convince 
colleagues and the public, Barry Marshall drank a suspension of bacterium [Marshall 
B.J., et al. 1985]. However, it was not until the early 1990s that it was recognized that H. 
pylori causes peptic ulcer disease. During that period, several researchers confirmed 
that H. pylori eradication cured peptic ulcer [Coghlan et al. 1987], [Rauws et al. 1990], 
[Graham et al. 1991]. In retrospect, it is interesting to notice that there were many 
references to the presence of H. pylori in gastric mucosa before its culture in 1982. 
Spiral-shaped bacteria were noted many times in the literature, but their presence was 
not properly correlated with gastro-duodenal disease [Mobley et al. 2001], [Marshall, 
2001]. H. pylori is, by bacteriological standards, a relative newcomer to medicine. 
Although its pathogenesis has been studied for the past 20 years, there are reports from 
as far back as the late 19th century of small, helical bacteria in the stomachs of some 
patients. One of the first well known reports of gastric helicobacters was done by 
Bizzozero in Turin in 1893 [Bizzozero G., 1893]. The bacterium was initially named 
Campylobacter pyloridis, then C. pylori (after correction to Latin grammar). In 1989, after 
DNA sequencing and other data had shown that the bacterium did not belong to the 
Campylobacter genus, it was placed in its own genus, Helicobacter. The name pylōri 
means “of the pylorus” or pyloric valve (the circular opening leading from the stomach 
into the duodenum), from the Greek word gatekeeper. Presently, over 20.000 articles 
have been published on “helicobacter”, not counting the articles under the previous 
classification of “Campylobacter”. The bacterium has also been shown to play a role in 
the development of several types of gastric cancers. Indeed, the control of H. pylori, may 
soon be added to the list of high-priority cancer prevention strategies. H. pylori seems to 
have evolved together with humans over tens of thousands of years  and arguably has 
accounted for more deaths from cancer than has any other single carcinogen [Covacci 
A., et al. 1999]. Gastric cancer was the principal cause of worldwide cancer deaths, 
before being replaced by lung cancer at the end of the twentieth century. It was also the 
leading cause of cancer death in the United States until about 1940, and its decline in 
frequency since then probably represents an important and largely unappreciated 
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consequence of the sanitary revolution. Mortality rates for gastric cancer now vary 
profoundly around the world, with the greatest effect seen in much of Asia and Latin 
America. Some countries with a high prevalence of chronic H. pylori infection, such as 
South Africa and India, have low rates of gastric cancer and even within high-risk 
countries, such as China, Colombia, and Costa Rica, rates can vary greatly (Fig. 1.1). 
The reasons for these findings are not fully understood, but they may in part reflect 
variations in the distribution of the more virulent strains of H. pylori [Bravo LE., et al. 
2002]. As we learn more about the pathogenesis of H. pylori-induced cancer and about 
the immunologic mechanisms that contribute to chronic infection, the prospects for 
vaccine-based prevention strategies become increasingly bright. If we can prevent the 
acquisition of H. pylori infection, which in high-risk countries usually occurs in early 
childhood, we may virtually eliminate gastric cancer as an important cause of cancer 
death. Eradication of infection with antibiotic therapy seems to offer more promise, and 
the results of two clinical trials have provided encouraging, although not conclusive, 
evidence that antibiotic treatment of adults may prevent gastric carcinogenesis. H. pylori 
is notoriously difficult to treat, and the need to use a multidrug regimen over extended 
periods, as well as the emergence of resistant organisms, has complicated research 
and, ultimately, implementation programs aimed at eradication. However, the recent 
report of the effectiveness of a single-day regimen of combined antibiotic therapy in 
eradicating infection provides some encouragement that mass treatment programs may 
be feasible in future [Lara L.F., et al. 2003]. The current treatment against H. pylori 
infection consists of a combination of two antibiotics and a proton pump inhibitor. The 
major drawbacks to this therapy are high cost, poor patient compliance and risk of 
developing antibiotic resistance. Furthermore, such treatment does not protect against 
re-infection. Extensive research is going on to develop a vaccine against H. pylori that 
will have (a) prophylactic use to prevent infection and/or (b) therapeutic use to eradicate 
an ongoing infection. A prophylactic vaccine would primarily be useful in young children 
in high endemic areas, whereas a therapeutic vaccine may be the most relevant one for 
treatment for those that are already infected (Svennerholm A.M., and Lundgren A., 
2006). 
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Fig. 1.1: Geographic prevalence of H. pylori infection 
        
1.2 Helicobacter pylori 
 
Helicobacter pylori is a spiral-shaped Gram negative flagellated bacterium (Fig. 1.2) that 
infects the gastric mucosa of more than half of the world’s population, making it the most 
prevalent of all bacterial infections. The prevalence in developing countries can be as 
high as 80-90%, whereas it is lower in industrialized countries, ranging between 10-50 
% (Rothenbacker D., and Brenner H., 2003).  
 
 
Fig.  1.2: Image of H.  pylori by electronical microscopy 
 
 
H. pylori is an important cause of chronic gastritis, peptic ulcer disease and gastric 
cancer (Goodwin, C.S., 1997). The natural progression of H. pylori infection is presented 
in Fig. 1.3. Infection usually occurs during childhood and causes symptomatic acute 
gastritis in most patients and persists for decades or life-long; once acquired it, the 
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infection persists throughout life unless specifically treated. The infection can take 
multiple courses. Most people infected with H. pylori will never develop symptomatic 
disease. H. pylori-induced gastritis, during the decades that follow initial infection, can 
remain silent or evolve into more-severe diseases: 10-15 % will develop peptic ulcer 
disease (gastric or duodenal ulcers), approximately 1% will develop gastric 
adenocarcinoma, and a small group of patients will develop gastric MALT lymphoma 
(Sauerbaum S., and Josenhans C., 2007). Epidemiological studies first indicated that H. 
pylori-infected subjects have at least a twofold increase in the risk of gastric cancer 
when compared with uninfected subjects. The strong association between H. pylori 
infection and gastric cancer led the WHO to classify H. pylori as a class 1 carcinogen. In 
industrialised countries, the overall carriage rate of H pylori infection in middle-aged 
adults is 20–50%, compared with 80% or more in many developing countries. The 
carriage rate of H. pylori remains relatively stable, but in the industrialised world these 
values have substantially decreased over recent decades, probably as a result of 
improved hygiene and sanitation, especially during childhood, and active elimination of 
carrier ship via antimicrobial treatment. H pylori-associated disorders usually regress or 
heal completely after successful treatment of H pylori infection with antimicrobials. 
However, the available antimicrobial therapies for H pylori infection have many 
shortcomings e. g, side-effects, the need for combination therapy, and limited efficacy, in 
particular because of the development of antimicrobial resistance. The continuous 
increase in the prevalence of antimicrobial resistance in H pylori, together with the lack 
of forthcoming novel treatment options, already negatively affects eradication of H pylori 
infection, and is predicted to lead to serious problems for treatment of H pylori-
associated disorders in the near future. 
 
 
 
Fig. 1.3: Natural progression of H. pylori infection 
Acquisition of H. pylori usually occurs during childhood. Once acquired and left untreated, the infection 
persists for life. After the acute phase, most H. pylori positive patients develop a chronic gastritis without 
symptoms. In some patients, more severe manifestations will develop later in life. A normal or high acid 
secretion predisposes to duodenal ulcers, whereas a low acid secretion predisposes to gastric ulcers and 
gastric cancer. 
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The human stomach is a unique ecological niche characterized by very acidic pH a 
condition lethal for most microbes (Fig. 1.4). H. pylori is so well adapted to this 
unfriendly environment that, after the first infection, which usually occurs early in life, it 
establishes a life-long chronic infection. The extraordinary success of H. pylori in its 
hostile niche is indicative of very effective adaptation to these conditions. The selection 
of a niche with no competition and the ability to establish a chronic infection make H. 
pylori one of the most successful human bacterial parasites, which colonizes more than 
half of the human population. The successful life-lasting colonization of the human 
stomach by H. pylori is achieved through a combination of factors, which address the 
different challenges presented by the harsh environment. H. pylori synthesizes a urease 
to buffer the pH of its immediate surroundings within the stomach. Its helicoidal shape 
and the action of flagella allow it to cross the thick layer of mucus lining the stomach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. pylori then binds to Lewis antigens present on host gastric cells, and it secretes 
factors that attract and stimulate inflammatory cells, as well as the multifunctional toxin 
VacA. Last, the presence of the Cag pathogenicity island, a 40-kb DNA that encodes a 
type IV secretion system [Blaser M.J., et al.1995] seems to be necessary for optimal 
fitness of the bacterium and the appearance of pathogenic traits. Disease outcome is 
 
 Fig. 1.4: H. pylori adhesion to gastric mucosa 
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complex, because it depends on many factors, including bacterial genotype, host 
physiology, genotype and dietary habits.  
 
1.2.1 Bacteriology 
Helicobacter pylori is a micro-aerophilic, Gram-negative, slow-growing, spiral-shaped 
and flagellated organism. It is currently classified in the Proteobacteria, a large, diverse 
division of Gram-negative bacteria which includes, among others, H. influenzae and E. 
coli. The bacterium is a member of a rapidly growing genus. New species are being 
isolated at a fast rate from many vertebrate hosts. Also, other Helicobacter species are 
being isolated from no gastric sites in humans and may be implicated in diseases that 
previously had no assigned etiologic agent. H. pylori is motile via a tuft of polar-sheathed 
flagella; these structures also carry a terminal bulb, which perhaps makes it more 
adapted to swimming through mucus. The surface of H. pylori is the first point of contact 
between the pathogen and the host. The biology of this microbe-host interface is 
sophisticated and complex, and it is made by molecular constituents that account for 
many of the distinguishing properties of H. pylori. Surface proteins of H. pylori 
mediate important pathogen-host interactions that are essential for colonization, 
adherence, survival, and virulence of this pathogen. Moreover, those proteins, that are 
particularly accessible to host immune responses and to drug therapy, could be used to 
control this important human pathogen. On its surface, the lipopolysaccharide (LPS) has 
unique biological properties and the genes that control addition of the O-side chains can 
make a phase variation, a mechanism for avoidance of host responses. In addition, it 
has a unique peptidoglycan structure that differs from other gram-negative bacteria 
[Appelmelk B.J., et al.1996]. Availability of genome sequence of this pathogen has 
provided a tremendous amount of information that can be useful in a major 
understanding of virulence mechanism  and also in drug target and vaccine target 
identification. There is unique features of H. pylori genomic organisation. A milestone in 
microbial genomics was set when H. pylori became the first bacterial species to have its 
genome sequenced and compared from two independent isolates. The subsequent 
comparison has provided the first detailed look at the physical chromosomal 
organization and has begun to identify a minimal set of common genes that can be used 
as candidates for therapeutic strategies. There have been 1590 putative open reading 
frames (ORFs) identified in H. pylori 26695 circular chromosome (~1.7 Mbp). Almost 
60% of the ORFs have a predicted function, whereas 24% are conserved in other 
bacterial species but  are of unknown function and 17% are H. pylori specific with no 
known homologues in the current databases. These ORFans may encode proteins 
unique to H. pylori and provide selective targets for antibiotic therapy. The sequenced 
genome revealed a profile of an organism that was fine-tuned for its niche in the gastric 
mucosa, lacking many of the regulatory features found in the larger E. coli genome. (By 
contrast to the E. coli gene sequence, regulatory sequences have been identified in H. 
pylori 3-10 time less). Tight regulation of gene expression is imperative for entero-
pathogenic bacteria whether they are continually responding to the harsh acidic 
environment of the stomach or bile salts in the intestine. The remarkable economy of 
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regulatory elements in H. pylori may reflect the very limited range of environments in the 
which it survives, suggesting a highly evolved inter-relationship between man and 
microbe. One intriguing feature of the genomic organization is that ~1% of the genome 
of H. pylori encodes a family of 32 outer-membrane proteins that are well conserved 
between the J99 and 26695 strains. The  OMPs identified provide a tractable subset of 
the total genome, comprising most of the proteins known to be involved in virulence (for 
example, those required for adherence to gastric epithelial cells and evasion of the 
immune system). Of particular interest is the presence of tandem repeat sequences 
upstream of some OMPs. In other mucosal pathogens increasing or decreasing the 
numbers of repeats by slipped-strand mispairing and recombination affects transcription 
of the downstream genes. The extensive use of slipped strand mispairing is a clever 
form of regulation that allow the organism to present many faces to the host in terms of 
expression of outer membrane proteins and other surface structures. In this way minor 
reversible mutations rapidly change the antigen profile of the pathogen, leading to 
evasion of the host immune system. Numerous restriction-modification systems are 
present in this species, but they differ between the two genomes analyzed. There are 
more than twenty homologues associated with DNA restriction and modification systems 
identified in other bacteria, including type I, type II, and type III systems. The role of 
these enzymes is unclear at present. It has been suggested that the enzymes are 
involved in the breakdown of intracellular and/or intercellular DNA or that they are 
necessary for stimulating the formation of recombinants by DNA fragmentation. The 
presence of the cag pathogenicity island was identified prior to the sequencing of the 
whole genome, revealing a 40-kb stretch of DNA whose presence correlates with more 
virulent isolates. Most of the traditional protein secretion systems are encoded in the H. 
pylori genome, including ABC transporters, sec-dependent (leader peptide) transport, 
flagellar assembly (a prototype of the type III secretion system), type IV secretion 
homologues in the pathogenicity island, and auto-transporters such as VacA [Szabò I., 
et al. 1999]. H. pylori populations are extremely diverse at the genomic level. Moreover, 
a single host can carry several H. pylori strains, and isolates within an individual can 
change over time, as endogenous mutations and/or chromosomal rearrangements or 
recombination between strains occur. The comparison of H. pylori isolated from patients 
of different ethnical origin and geographical locations indicates that their nucleotide 
sequences segregate similarly to those of humans. This suggests that this bacterium 
was already present in the stomach of humans when they left Africa to colonize the 
world, and co-evolved with them since then. It is possible individuate two groups within 
the H. pylori proteome: 
 
1) Proteins involved in the adaptation of H. pylori to the gastric environment: 
 
To survive in the extremely acidic gastric lumen, H. pylori utilizes unique mechanisms, 
the most efficient of which is ammonia production by the potent nickel-containing urease 
(Fig.1.5). H. pylori expresses large amounts of urease, and levels can reach up to 10% 
of total cellular protein . Urease contains 12 nickel atoms per molecule, and thus H. 
pylori has a relatively high demand for nickel. Urease plays a central role in the 
pathogenesis of H. pylori infection and catalyzes the conversion of urea into carbon 
dioxide and ammonia. The latter is able to neutralize gastric acid and offer protection to 
H. pylori against the low pH in the stomach. In addition, ammonia may be used as a 
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nitrogen source supporting growth of H. pylori. Urease is regulated by an intricate 
interplay of different environmental signals such as the concentration of urea and metal 
ions, or the pH. The activity of urease critically depends on the availability of nickel ions, 
as a functional urease complex requires 24 Ni2+ [Eaton K.A., et al. 1991]. H. pylori also 
possesses a NixA nickel specific permease; accessory proteins (UreE and Hyp), 
required for proper maturation of nickel enzyme; and a histidine and cysteine-rich heat 
shock protein HspA; Hpn and Hpn-like proteins, which are transcriptionally activated in 
the presence of nickel by a nickel sensor system. These elements are the major 
contributors to nickel bioavailability either through sequestering or transporting nickel ion 
proteins. Their synthesis in cells depends on the Nickel responsive transcriptional 
regulator  NikR, wich together with the Iron dependent regulator Fur was found to be 
necessary  for efficient colonization of the mouse stomach by H. pylori. Two other 
ammonia-producing enzymes, AmiE and AmiF amidases, together with the arginase 
RocF, which generates urea from arginine, have been implicated in adaptive 
mechanisms to the low pH environment of the gastric lumen. Finally, the bacterium must 
deal with reactive oxygen species that are generated by phagocytic cells of the host 
immune response. In H. pylori, genes encoding superoxide dismutase (SOD), catalase, 
and several putative peroxidases have been identified. H. pylori has a potent set of 
antioxidant defences. Persistent colonization of H. pylori in a mouse model appears to 
require the function of  these gene products: sodB, katA (which encodes for  catalase 
KatA) and kapA (KatA-associated protein, that is an important component of the 
bacterium's resistance to oxidative damage, especially hydrogen peroxide). The 
expression of sodB (which encodes for iron-cofactored SodB protein) is essential for 
gastric colonization and also required for growth under microaerophilic conditions 
[Moobley et al. 2001]. 
 
 
Fig. 1.5: Urease Hidrolysis 
 
2) Main proteins involved in H. pylori pathogenicity mechanisms: 
 
Numerous studies have focused on the elucidation of H. pylori pathogenicity 
mechanisms. The cag-Pathogenicity Island (PAI), consisting of a group of 31 genes 
involved in the biogenesis of a type IV secretion system (T4SS) and the translocation of 
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the immune-dominant CagA antigen, has been shown to contribute to the induction of 
the pro-inflammatory IL-8 cytokine by host epithelial cells through the activation of the 
nuclear factor B (NF B) pathway, and thus has been recognized as one of the major 
pro-inflammatory players. T4SSs are ubiquitous secretion machineries formed by at 
least 12 proteins named VirB1-B11 and VirD4, three of them (VirB4, VirB11, and VirD4) 
are ATPases believed to power the assembly of the T4SS and drive substrates through 
it.  The vacuolating cytotoxin (VacA) is also one of the most studied virulence factor of 
H. pylori. VacA is thought to interfere with intracellular vesicles trafficking and its role in 
the persistence of the bacterial infection has been recently proposed [Gebert B., et al. 
2003]. Adhesion of H. pylori to gastric epithelial cells is another important early step in 
the infection process. One of the most studied adhesins is the blood-group antigen 
binding adhesin named BabA, encoded by the babA2 gene. Other adhesins have been 
described such as AlpA-AlpB, SabA or HopZ (Mahdavi et al. 2002], [Odenbreit S., et al. 
2002]. 
1.2.2 Complete Sequencing of  H. pylori genome 
Prior to the sequencing and annotation of the genomes of H. pylori strains 26695 and 
J99, a large number of studies had elucidated central metabolic pathways, uptake and 
regulatory systems, responses to various stresses, and virulence factors. Nevertheless, 
the publication of the genomes has had a marked impact on our knowledge of the 
bacterium, and the data derived from these sequences have served to confirm 
experimental results, to provide insights into the biology of the bacterium, to deepen our 
understanding of its diversity, and to suggest new areas of investigation [Tomb G.C., et 
al. 1997]. Helicobacter pylori, strain 26695, has a circular genome of 1,667,867 base 
pairs and 1,590 predicted coding sequences (Fig. 1.6). Sequence analysis indicates that 
H. pylori has well-developed systems for motility, for scavenging iron, and for DNA 
restriction and modification. Many putative adhesins, lipoproteins and other outer 
membrane proteins were identified, underscoring the potential complexity of host–
pathogen interaction. Based on the large number of sequence-related genes encoding 
outer membrane proteins and the presence of homopolymeric tracts and dinucleotide 
repeats in coding sequences, H. pylori, like several other mucosal pathogens, probably 
uses recombination and slipped-strand mispairing within repeats as mechanisms for 
antigenic variation and adaptive evolution. Consistent with its restricted niche, H. pylori 
has a few regulatory networks, and a limited metabolic repertoire and biosynthetic 
capacity. Its survival in acid conditions depends, in part, on its ability to establish a 
positive inside-membrane potential at low pH. The whole-genome analysis of H. pylori 
gives new insight into its pathogenesis, acid tolerance, antigenic variation and 
microaerophilic character. The availability of the complete genome sequence will allow 
further assessment of H. pylori genetic diversity. This is an important aspect of H. pylori 
epidemiology as allelic polymorphism within several loci has already been associated 
with disease outcome. It is predicted that a relatively high percentage of genes involved 
in central metabolic pathways will be essential for its survival even if their direct 
equivalents in other organisms are not. The products of these highly diverged essential 
genes merit further investigation as potential targets for novel, highly specific anti-H. 
pylori agents. The identification of many new putative virulence determinants should 
allow critical tests of their roles and thus new insight into mechanisms of initial 
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colonization, persistence of this bacterium during long-term carriage, and the 
mechanisms by which it promotes various gastroduodenal diseases. 
 
 
 
Fig. 1.6: Circular representation of 
         the H. pylori 26695 chromosome 
 
1.2.3 Surface Localization of Cytoplasmic Proteins. 
The cell surface of H. pylori has the unusual property of being able to incorporate 
proteins such as urease, catalase, HspA, HspB, and superoxide dismutase (SOD), 
which are found virtually exclusively within the cytoplasm in other bacteria. Cryo-
immunolocalization techniques have demonstrated that urease, catalase, and HspB are 
located strictly within the cytoplasm of freshly subcultured, early log-phase H. pylori. 
However, at the end of the log-phase, these proteins are also surface associated or 
extracellular. Significant fractions of urease and HspB are also surface associated in 
vivo. Indirect gold immune-staining of H. pylori SOD with a polyclonal antibody directed 
against the iron-containing SOD of E. coli showed a surface localization of the enzyme. 
Gold particles were distributed on the cell envelope and on the sheath of the flagella. 
SOD was located on the outer surface of a limited number of bacteria, but the enzyme 
was cytoplasm in most cells.  
In contrast to other H. pylori proteins with specific secretion pathways, the mechanism 
whereby urease, HspA, HspB, catalase, and SOD become associated with the other 
membrane of H. pylori is controversial. Urease, HspA and HspB are large oligomeric 
proteins that are typically found exclusively in the cytoplasm of bacteria and would not 
be expected to cross the bacterial outer membrane. H. pylori urease, HspA and SOD, 
and catalase have been shown genetically to lack leader peptides.  Alternative transport 
mechanisms must therefore exist. The ability of released cytoplasmic proteins of H. 
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pylori to bind to the cell surface is considered to be biologically important. Some very 
elegant work [Phadnis S.H., et al.1996], [Vanet A. And Labigne A. 1998] has shown that 
although H. pylori urease, HspA, HspB, and catalase are intrinsic cytoplasmic proteins in 
log-phase bacteria, these proteins become associated with the outer membrane of H. 
pylori when they are released from the cytoplasm by autolysis of a fraction of the 
bacteria. They then become adsorbed to the surface of intact bacteria. Although specific 
export of these proteins cannot be completely excluded, it can be envisaged that the 
“altruistic autolysis" process aids in protection against environmental stresses and 
functions in diversion of the immune response of the host (Fig.1.7).  
The ability of released cytoplasmic proteins of H. pylori to bind to the cell surface is 
considered to be biologically important. For example, the surface locations of catalase 
and SOD could enable these enzymes to function more effectively as a defense 
mechanism against phagocytic attack. In the case of urease, one study indicated that 
free or extracellular urease is irreversibly inhibited at  pH <4.5. The authors concluded 
that external urease is ineffective as an acid-protective device at the lower pH values in 
the stomach. However, in another study, bacteria with only cytoplasmic urease showed 
significantly reduced survival when exposed to acid in the presence of 5 mM urea when 
compared to the survival of bacteria with both cytoplasmic and extracellular urease. This 
indicates that cytoplasmic urease activity alone is not enough to enable H. pylori to 
survive in acid. The authors of this study speculate that the association of urease with 
the outer membrane of H. pylori protects urease from inactivation by acid. Development 
of mutants in which urease is located strictly within the cytoplasm would be helpful to 
resolve the discrepancies between the two studies. In addition to mediating acid 
resistance, other roles have been postulated for surface-associated urease that include 
binding to mucin at acidic pH. The observation that urease, HspA, HspB, and catalase 
are surface associated helps explain how they can serve as vaccine components in 
animal trials. However, it is likely that in vivo a subpopulation of H. pylori cells do not 
carry these antigens on the cell surface, and such a subpopulation may therefore evade 
the protective effect of the vaccine. Characterization of the cell envelope of H. pylori has 
identified a number of important features that distinguish it from other bacterial 
pathogens. These are the simple structure of its peptidoglycan, its unusual cellular fatty 
acid and lipid profile, molecular mimicry of Lewis antigens by lipopolysaccharide (LPS) 
and the presence of cytoplasmic proteins such as urease, Hsps, and SOD on the cell 
surface.  
In addition to these characteristics, polar flagella and a unique repertoire of outer 
membrane proteins are all likely to contribute to the ability of the organism to colonize 
the stomach and cause disease. The significance of the outer membrane components, 
many of which are likely to function as adhesins, is highlighted by the fact that H. pylori 
devotes a significantly high proportion of its coding capacity to them. Many of the 
vaccine candidates for H. pylori are proteins found on the cell surface, underlining the 
importance of further characterization of these proteins and of elucidating the precise 
mechanism of interaction between H. pylori cell surface and gastric mucosa. 
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Fig 1.7: Autolysis of H. pylori: 
Hypotetical model that explains how the bacterium is able to answer against external signals, 
activating a genetic program of autolysis. This mechanism is responsible for cytoplasmatic protein’s 
releasing, such as urease, catalase and Heat shock proteins (Hsp). 
 
 
 
1.3 H. pylori Heat shock protein A (HspA) 
 
 
1.3.1 GroEL and GroES chaperones 
 
Heat shock protein A is a unusual GroES homologue. In general, these proteins are 
involved in the intracellular folding and assembly of various polypeptide chains into 
oligomeric complexes [Horwich A.L., et al. 2007]. Heat shock proteins (Hsp) of the 
GroEL/GroES class are a highly conserved group of proteins found in all domains of life. 
Despite their designation, they are expressed at a low level and play a vital role at all 
temperatures in maintaining normal cell function. Increased synthesis of these proteins 
occurs in response to many environmental stresses, including temperature changes 
(hence their name), oxygen limitation, glucose limitation and iron deprivation for 
bacteria, but also, as far as eukaryotic cells are concerned, inflammation, irradiation, 
malignant transformation and T-lymphocyte activation with mitogens or lymphokines. 
These proteins are involved in the intracellular folding and assembly of various other 
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polypeptide chains into oligomeric complexes, without becoming part of the mature 
products.  
The bacterial Hsp60 chaperonin (GroEL homologue) act together with the Hsp10 protein 
(GroES homologue). Both form homo-oligomers of two stacked rings, each ring having a 
seven-fold symmetry. The present view of the mechanism by which they act suggests 
that the Hsp60 alone interacts with the unfolded polypeptide, subsequently the Hsp10 
binds to the Hsp60-polypeptide complex and plays a role in the release of the 
polypeptide by modulating the ATPase activity of the Hsp60 moiety. The Hsp10 and 
Hsp60 proteins are commonly encoded by a single bi-cistronic operon that leads to the 
coordinated expression of the two genes. The thermo-inducible nature of the heat-shock 
genes depends upon the bacteria. Two major mechanisms of regulation at the 
transcriptional level have been identified: 
 
I. In most bacteria the genes are induced by activating transcription from promoters 
specifically recognized by an RNA polymerase containing the Sigma 32 factor 
(σ32). Therefore, the level of expression of the hsp genes is directly proportional 
to the amount of the σ32 factor present in the cell, encoded by the rpoH gene. 
 
II. A second mechanism involves the presence of a conserved motif forming a 
hairpin-loop structure, TTAGCACTC-N9-GAGTGCTAA, located between a 
vegetative promoter sequence and the start site of the structural gene. This motif 
is known as CIRCE (controlling inverted repeats of chaperone expression). 
 
 
Interestingly, none of the two regulation systems mentioned above have been identified 
in the H. pylori hsp gene cluster. It seems that the Hsp10 and Hsp60 proteins have vital 
functions for H. pylori, since the attempts to construct H. pylori mutants in which either 
the hsp60 or the hsp10 gene has been disrupted have been unsuccessful. 
          
1.3.2 H. pylori HspA: 
The transition metal nickel plays a central role in the human gastric pathogen 
Helicobacter pylori because it is required for two enzymes indispensable for colonization, 
the nickel metalloenzyme urease and [NiFe] hydrogenase. To sustain nickel availability 
for these metalloenzymes while providing protection from the metal's harmful effects, H. 
pylori is equipped with several specific nickel-binding proteins, an assortment of factors 
in order to adapt itself to the extremely acidic environment of the stomach?? Among 
these, H. pylori possesses a particular chaperone, HspA, that is a homolog of the highly 
conserved and essential bacterial heat shock protein GroES. No other gene encoding a 
GroES homolog is found in the genome of H. pylori. It shows an extended subcellular 
localization, ranging from cytoplasm to the bacterial cell surface Indeed, H. pylori HspA 
consists of 118 amino-acids divided in two domains: an N-terminal domain (domain A, 
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residues 1-90), which is homologous with other GroES bacterial proteins, and a C-
terminal domain (domain B, residues 91-118), which other GroES-like proteins lack and 
which contains eight His and four Cys residues among 27 amino acids (Fig. 1.8). This 
His/Cys-rich C-terminal extension is unique and was demonstrated to bind nickel in vitro 
[Kansau I., et al.1996]. 
Whilst H. pylori GroEL-like (Heat-Shock protein B, HspB) was shown to be very similar 
to other bacterial GroEL-homologues, H. pylori HspA appeared to be unique in 
sequence and  structure. The domain B sequence is restricted to H. pylori and the 
closely related Helicobacter acinonychis species but is absent from all other available 
sequenced Helicobacter species. This domain also contains an HX4DH motif that is 
considered to be a nickel-binding signature sequence in the nickel-cobalt (NiCoT) 
transporter family. Besides its usual co-chaperone activity, HspA plays two additional 
roles, being involved in nickel binding and urease activity, it facilitates nickel acquisition 
by donating it to appropriate proteins in a Ni(II)-deficient environment and carries out 
detoxification via sequestration of nickel excess. 
This striking C-terminal domain of HspA was found only in H. pylori 26695, H. pylori J99 
and H. acinonychis genomes.  
 
 
 
                                    
 
Fig 1.8: Schematic representation of the GroES-like domain A and the nickel-binding domain B of  
H. pylori HspA. 
 
 
 
 
A very unique characteristic of HspA among all GroES proteins is a very high content of 
cysteine residues, although these amino acids are the less represented residues in all 
GroES proteins examined so far. Indeed the protein sequence contains 6 cysteines (two 
in the A domain and four in the B domain) whereas cysteine is the less represented 
residue in all GroES proteins examined so far. It can be deduced that cysteine is not an 
essential residue for chaperonins, and hence HspA has to play additional roles mediated 
by its unusually high number of Cys residues (Fig. 1.9). 
The B domain is highly charged and it exhibits a high and specific affinity for nickel ions 
in comparison with its affinity for other divalent cations (copper, zinc, cobalt). It has two 
distinct Ni2+-binding sites: a high-affinity site with Kd ~ 2.8 μM and a lower-affinity site, 
which binds Ni2+ at concentrations above 30 μM. The presence of a C-terminal histidine-
rich domain associated with nickel binding has already been described in other bacteria, 
for UreE, a nickel carrier protein that is expressed by most of the urease gene clusters 
as one of the accessory proteins required for urease metallocentre assembly (i.e. 
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activation of the apo-enzyme). Curiously, none of the H. pylori accessory proteins, 
including the H. pylori UreE homologue, exhibits such a nickel-binding motif. This led to 
speculate that there might be a link between HspA and the nickel-containing urease 
enzyme. So far, however, all attempts to visualize a complex consisting of the 
polypeptides UreA, UreB, HspA and/or HspB have been unsuccessful. Interestingly, 
evidence for a possible interaction of HspA with the H. pylori urease holo-enzyme was 
provided by a genetic approach. In fact, the co-expression in E. coli of the urease gene 
cluster and of the HspA gene leads to a fourfold increase of urease activity when 
compared to the expression of the urease gene cluster alone.  
A recent study [Cun S., et al. 2008] found that HspA binds Bi3+ with high affinity via 
coordination to cysteine residues. Therefore bismuth is a commonly recommended 
metallodrug for the treatment of  H. pylori infections. This study showed, that HspA 
reversibly binds two Ni(II) ions/monomer with moderate binding affinity, whereas two 
Bi(III) ions bind to the protein incomparably stronger inducing the changes in quaternary 
structure (from native heptamer to a dimer). The binding is irreversible at physiological 
pH, which clearly indicates that bismuth may interfere with the biological functions of 
HspA. It is probably the C-terminal His- and Cys rich domain which is beneficial in nickel 
resistance but harmful to cell growth when exposed to bismuth. Therefore, it seemed 
interesting to compare the interactions of Ni(II) and Bi(III) with the C-terminal domain, 
and also to have a closer look at the interactions of these metals with His- and Cys-rich 
peptides in general.  
 
 
 
Fig. 1.9: Amino acid sequence of HspA: in the be domain we can observe 8 His residues evidenced in 
red, and 4 cys residues evidenced in yellow. 
 
 
 
HspA exhibits another important feature: it is known to be immunogenic. The immune 
response to this protein in H. pylori-positive adults increases with age. Among many 
clinical isolates tested, the A domain is highly conserved, whereas the B domain 
encompasses two variant type sequences that differ from each other by the 
simultaneous substitution of seven amino acids. Interestingly, none of the substitutions 
affects the hystidine and cysteine residues. The different domains of HspA elicit distinct 
host immunological responses, and the A domain was found to be the immune-dominant 
domain. In 1996, Labigne et al. demonstrated that both HspA and HspB confer 
Domain A
MKFQPLGERVLVERLEEENKTSSGIIIPDNAKEKPLMGVVKVSHKISEGCKCVKEGDVIAFGKYK
GAEIVLDGTEYMVLELEDILGIVGS
1 65
66 90
Domain B
GSCCHTGNHDHKHAKEHEACCHDHKKH
91 118
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protective immunity against mucosal infection in mice. Since then, the development of 
HspA-based vaccines against H. pylori became an active research field. H. pylori HspA 
is particularly appealing as a vaccine component because it has a unique structure, with 
the C terminal domain which is absent from other known heat shock homologues, 
including those of eukaryotic organisms. Moreover, the capacity of this domain to bind 
nickel ions facilitates large-scale purification of the polypeptide. Lastly, this antigen is 
also expressed by all the isolates and is highly conserved at the amino acid level.  
It is worth noting that HspA is the only nickel chaperon which was found to be surface-
associated among the several nickel-binding and accessory proteins facilitating Ni-
enzyme maturation in H. Pylori [Cun S., et al. 2008]. 
Several mechanisms have been proposed for the HspA extracellular release, including 
specific secretion pathways, autolysis, and membrane vesicle formation, but a 
conclusive explanation is still missing. Therefore, the protein experience different pH 
and redox  environments when it moves from the bacterial cell to the extracellular space. 
In conclusion, HspA plays a critical role as a specialized nickel chaperone . Because 
nickel ions play a crucial role during H. pylori colonization but seem not to be utilized by 
humans, the nickel metabolism of H. pylori is an attractive therapeutic target, particularly 
in the age of increasing microbial antibiotic resistance. Our study thus provides key 
insights for the development of alternative antimicrobials. 
 
1.4 Coenzyme A, central to metabolism 
Research involving Coenzyme A has always been popular due to its biochemical 
centrality. Coenzyme A (CoA) is a ubiquitous and essential cofactor in all living 
organisms [Leonardi  R., et al. 2005]. The German biochemist Fritz Lipmann discovered 
CoA in 1945. He was the first to show that a coenzyme was required to facilitate 
biological acetylation reactions. In 1953, Lipmann was awarded the Nobel Prize in 
physiology and medicine for his pioneering work in elucidating the role of this important 
coenzyme [ Baddiley J., et al. 1953]. It functions as an acyl group carrier and acyl 
activating group in a number of central metabolic transformations, including the 
tricarboxylic acid cycle and fatty acid metabolism. It has been estimated that CoA and its 
thioester are involved in over 100 different reactions in intermediary metabolism of 
microorganisms. As a result of CoA’s ubiquitous nature and its role as a cofactor in 
metabolism, its levels must be stringently regulated. In addition to this, the CoA 
biosynthetic pathway is an energetically expansive pathway, so it makes sense that the 
pathway itself be regulated as not to waste cellular energy. The biosynthetic pathway 
from pantothenate to CoA is essential in both  prokaryotes and eukaryotes. CoA is 
produced through a series of five enzymatic reactions from pantothenate or vitamin B5. 
All the genes coding for the enzymes that catalyze  the reactions in the biosynthetic 
pathway are known.  
The biosynthesis of CoA can be divided into two parts in bacteria. First, pantothenate is 
synthesized, where after the universal biosynthesis of CoA from pantothenate occurs. 
The second part of the pathway is present in most organisms, and the best 
characterized CoA pathway is those of E. coli. Pantothenate is one of the B complex of 
vitamins (vitamin B5) and it plays a fundamental role in all organisms. Animals and some 
microbes lack the capacity to synthesize pantothenate and are totally dependent on the 
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uptake of pantothenate in their diets. However, most bacteria, plants and fungi are 
capable of synthesizing panthotenate. As a result of pantothenate being found vitually 
everywhere in biology it was designated pantothenate, which is derived from Greek 
“pantothen” meaning “from everywhere” .  
 
 
1.4.1 The Pantothenate Biosynthetic Pathway in E. coli: an overview 
The biosynthesis of CoA begins with the decarboxylation of aspartate to give β-alanine. 
Pantoic acid is formed by the hydroxymethylation of a α-ketoisolverate followed by 
reduction of ketopantoate (Fig. 1.9). Pantoic acid and β-alanine are then condensed to 
generate pantothenic acid. Bacteria divert amino acids and intermediates from central 
metabolism to produce pantothenate [Song W.J., et al. 1992]. All the enzymes which are 
involved in this biosynthetic pathway are also important as research candidates. The 
CoA and its thioesters production must be tightly controlled to prevent metabolic activity 
running away.  CoA levels are regulated in one of five ways: 
 
 
 The compartmentalization of CoA 
 Feedback regulation by Pantothenate kinase 
 Secondary regulation by adenyltransferase 
 Rgulation of CoA levels by gene expression 
 Regulation by degradation 
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Fig. 1.9: A schematic illustration of the complete biosynthetic pathway of CoA in E. coli 
 
1.4.1.1 Phosphorylation of Pantothenate 
Pantothenate Kinase, also known as PanK or CoaA, catalyses the ATP-dependent 
phosphorylation of pantothenate to form phosphopantothenate (Fig. 1.10). This is the 
first committed step in the biosynthesis of CoA, since none of the phoshorylated 
intermediates formed in the subsequent reactions can enter the cell. It catalyzes the 
transfer of the terminal phosphate from ATP to pantothenate, forming 
phosphopantothenate. Pantothenate kinase is encoded by the CoaA gene. Because of 
CoA’s metabolic centrality, the enzyme(s) that regulated its production is of paramount 
importance. Pantothenate kinase is the key regulatory point in the control of CoA levels 
in the cell. It is subject to feedback inhibition by CoA itself and to a lesser extent by CoA 
thioesters.  
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Fig. 1.10: PanK reaction 
 
This is shown by the work done by Song et al, who discovered that a 76-fold 
overexpression of PanK only resulted in a 2.7 fold increase in the cellular concentration 
of CoA. This feedback inhibition of Pank by the different CoA molecular species controls 
the overall CoA availability in response to the cell’s metabolic status.  
The crystal structure of E. coli PanK in complex with either ATP or CoA has been 
determinate. Based on this structural data, Rock et al. set about designing three site-
direct mutants of PanK that were predicted to be resistant to feedback inhibition by CoA, 
based on decreased binding efficiencies of this inhibitor. These mutants were shown to 
retain significant activity and be refractory to inhibition of CoA. In particular, the 
presence of the Arg106 which is replaced in one of mutants (this residue does not have 
a role in a catalysis reaction) is postulated to be an important and specific requirement 
for CoA binding since it forms a salt bridge with the phosphate attached to the 3-
hydroxyl of the CoA ribose. The authors show that the mutants that are refractory to 
feedback inhibition accumulate intracellular phosphorylated pantothenate-derived 
metabolites, thus translating into a higher CoA content. This data confirms that the 
feedback inhibition is operating in vivo to limit the amount of CoA being produced. The 
cloning of the first eukaryotic PanK from fungus revealed a sequence completely 
different  from E. coli PanK. However,  this protein from Aspergillus nidulans is 
homologous to several proteins encoded by mammalian genes. This discovery (that the 
Pantothenate
4’-phosphopantothenate
PanK, CoaX
ATP
ADP
Cysteine
4’-phosphopantothenylcysteine
CO2
coaD
DephosphocoenzymeA
ATP
ADP
CoenzymeA
4’-phosphopantotheine
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bacterial PanKs were different from mammalian PanKs) led to the prediction that the 
pantothenate kinase step was a prime target for the identification and design of  novel 
antibacterial drugs. The development of new antibiotics designed as inhibitors of CoA, 
utilizing enzymes (such as CoA antimetabolites) would be very beneficial. 
 
1.4.2 Pantothenate kinases, different types 
Currently two types of the enzyme have been characterized: the first (Type I) is found 
predominantly in prokaryotic organisms and is exemplified by the Escherichia coli PanK 
enzyme. The second (Type II) occurs mainly in eukaryotic systems, of which the murine 
enzyme has been the best characterized. These enzymes exhibit wide variations in their 
distribution, mechanisms of regulation and affinity for substrates. The Type I and II show 
very little sequence similarity and are predicted to be structurally distinct. Despite this, 
they share a common regulation mechanism based on feedback inhibition by CoA and 
its thioesters, although the degree of inhibition is system and inhibitor dependent. This 
feedback mechanism is primarily responsible for controlling the intracellular CoA 
concentration. 
 
1.4.2.1 Type I Pantothenate kinase 
The pantothenate kinase enzyme was first identified in S. typhimurium and E. coli and 
thereafter in numerous other bacteria by comparative genomics. Type I PanK from E. 
coli (EcPanK) is a homodimeric enzyme; it has been extensively structurally 
characterized through X-ray analysis of its complexes with CoA, with an analogue of 
ATP, and with ADP and pantothenate It is considered the prototypical bacterial PanK. A 
survey conducted by Cheek et al. has characterized all known kinases into specific 
groups and families based on their three dimensional structure. The PanK from E. coli is 
structurally distinct from its eukaryotic counterpart. Based on the crystal structure of the 
Type I PanK the authors place this type into the Rossmann-like fold group (group 2). 
Within this group they are classified into the P-loop kinase family. The P-loop family 
constitutes the largest family in the Rossmann-like fold group. Although the E. coli PanK 
is considered the model bacterial Pantothenate kinase, this type is not universally 
expressed in bacteria. For example, the eubacteria Pseudomonas aeruginosa and 
Helicobacter pylori do not have recognizable pantothenate kinases in their genomes, 
although all other components of the biosynthetic pathway are present. 
 
 
1.4.2.2 Type II Pantothenate kinase 
Mammalian Pantothenate kinase belongs to the group of Type II Pantothenate kinase. 
Of the mammalian PanKs, perhaps the best characterized is the murine PanK. The 
murine Patothenate kinase (PanK1) gene is located on Chromosome 19: two 
biochemical distinct isoforms named PanK1α and PanK1β are encoded by this PanK1 
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gene. The two isoforms differ with regards to their regulatory properties. The isoforms 
are differentially expressed in mouse tissue as a result of metabolic status of the tissue 
[Rock C.O., et al. 2002]. 
The Asperigillus nidulans  PanK, also characterized as a Type II PanK, is sensitive to 
inhibition by acetyl-CoA but not effect, positively or negatively, by CoA. It is clear that  
the characteristics of the eukaryotic (Type II) PanK are in sharp contrast to the 
prokaryotic (Type I) PanK in terms of inhibition, with Type I PanKs being inhibited 
predominantly by CoA and to a lesser extent acetyl-CoA, and the Type II PanKs being 
inhibited more potently by acetyl-CoA. Unlike the Type I, which belong to the P-loop 
family of kinases, the Type II PanKs are predicted to belong  to the Ribonuclease H-like 
kinase group. The ribonuclease H-like group belongs to the ASKHA (acetate  and sugar 
kinase/hsc70/actin) superfamily. These structures are characterized by the duplicate 
domains of the Ribonucleasi H-like fold. Looking at the PanK from Staphilococcus 
aureus it is evident that this is an atypical Type II PanK. Even though S. aureus is a 
bacterium, its PanK sequence is distinctly different from that of E. coli. In fact, it is more 
closely related to the mammalian PanK than to those of its fellow bacteria. S. aureus’ s 
PanK sequence shares 18% identity with the murine PanK isoform 1β and only 13% 
identity with E. coli PanK. The native molecular mass of S. aureus PanK is 59 kDa, 
which is consistent with the existence of a homodimer. All organisms characterized to 
date share a common mechanism to regulate CoA biosynthesis, feedback inhibition by 
CoA and/or its thioesters. The key difference between S. aureus PanK and other 
pantothenate kinases is that it is refractory to feedback inhibition by CoA and its 
thioesters. S. aureus produces CoA in proportion to the input of β-alanine with no 
indication of regulation at PanK or in downstream reactions. This observation may be 
understood in the light of S. aureus physiology. S. aureus does not contain glutathione: 
so CoA is the primary intracellular thiol and together with a unique CoA disulphide 
reductase functions as the reducing system. Because of this the concentration of CoA in 
S. aureus can reach millimolar levels, and the lack of CoA inhibition regulation in this 
organism means that the upper limit of CoA is set by the availability of the starting 
materials of CoA biosynthesis, namely pantothenate and cysteine. 
 
1.4.2.3 Type III Pantothenate kinase 
As discussed, at least two types of PanK exist in nature. These types show very little 
sequence similarity and are predicted to be structurally distinct. However, sequence 
analysis of bacterial genomes, using these two types as template, fails to locate a 
homologue of either analogue in some species. Curiously the genomes of certain 
pathogenic bacteria,   do not contain a pantothenate kinase similar to either analogue, 
although these organisms possess all the other biosynthetic machinery required for CoA 
production. Since PanK activity is required for the biosynthesis of CoA in all living 
systems such as a gene must exist in these species. The group species lacking type of 
the currently identified PanKs can be separated into two subgroups: those belonging to 
the family of archeabacteria, and those that include well-known pathogenic eubacteria 
such as Bordetella pertussis, Helicobacter pylori and Pseudomans aeruginosa; whereas 
Bacillus subtilis and Mycobacterium tuberculosis have both type I and type III enzymes. 
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Since these organisms posses sequences that are homologues to all the other CoA 
biosynthetic genes, it is highly likely that at least one other analogue PanK exists that 
represents this activity in this bacteria. This type would have little or  no sequence 
similarity to the well-characterized types. Through a studies based on genome sequence 
of Bacillus subtilis it was possible identify a new gene named CoaX, which encodes a 
protein that exhibits pantothenate kinase activity. Homology searches based on the 
CoaX gene sequence identified orthologues in several bacterial genomes, including 
those eubacteria that do not posses another PanK analogue. In spite of current 
knowledge of CoA biosynthesis in general, and PanK enzymes in particular, the 
identification of this activity remains elusive in a subset of pathogenic bacteria, including 
H. pylori [Brand L.A., et al.2005]. This fact was highlighted in two recent studies, both of 
which used a comparative genomics approach to reconstruct the universal biosynthetic 
pathway in representative organisms of all kingdoms. Among these, H. pylori and P. 
aeruginosa are examples of bacteria in which no putative PanK similar to either known 
analogue could be found, even though the four remaining CoA biosynthetic enzymes 
were clearly represented. Since PanK  is an essential activity in these organisms, this 
suggests that at the least one additional, uncharacterized PanK exists. In comparison to 
the Type I and Type II PanKs, these CoaX enzymes exhibit distinctly different 
characteristics, suggesting  that they are the first characterized examples of Type III 
PanK analogue. The CoaX enzymes exhibit a very low specificity for ATP. This is due to 
their surprisingly high kM values, which is nearly 10 mM in the case of HpCoaX. These 
findings have important implications for the identification of new drug targets in 
pathogenic bacteria, as well as for the understanding of the convergent evolution of key 
metabolic enzymes. 
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Figura 1.11: The monomer consists of two “duplicated” domains that are considered to be a result of gene 
duplication. The same monomer creates different dimer interfaces in type II and III PanKs. This provides a 
structural explanation for the lack of inhibition by CoA and inability to bind Pan analogues observed in type 
III PanKs.  
 
 
 
1.4.2.4 Significance of the discovery of a third PanK analogue 
The discovery of a third type of pantothenate kinase gives a significant contribution to 
our understanding of how identical enzyme activities arise through convergent evolution. 
Additionally, since genomic analysis studies suggest that the CoaX homologues account 
for the only PanK activity found in pathogenic bacteria like H. pylori, the immediate 
implications for the development of specific and directed antibacterial agents are 
evident. 
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1.4.2.5 Inhibition of Type III PanKs by CoA and acetyl-CoA 
With the exception of the recently characterized S. aureus PanK enzyme, all other 
known PanKs are inhibited by CoA and/or its thio-esters. The extent of inhibition is 
system dependent: prokaryotic type I PanKs exhibit greater inhibition by free CoA than 
its thioesters, while the activity of eukaryotic Type II PanKs is effected more by the CoA 
thio-esters acetyl- and malonyl-CoA. In both cases the inhibition serves to regulate the 
intracellular CoA concentration by affecting the flux through the pathway. Differently 
neither of the CoaX enzymes is affected.  B. subtilis PanK (Bs-PanK) and H. pylori PanK 
(Hp-PanK) exhibit unique kinetic  characteristics, showing low specificity constants for 
ATP and no regulation by CoA and its thioesters. This is one of the main differences 
between them and the other PanK type classified to date. The only other PanK that 
shows a similar lack of inhibition is that of the recently classified S. aureus.  They do not 
accept the pantotenic acid  alkylopantenamides  as substrates, nor are inhibited by 
them, which also  distinguishes them from the atypical S. aureus enzyme. These 
properties all distinguish them from the other PanK type, and strongly suggest that they 
are the first characterized examples of the third analogue of PanK enzymes. It is still 
unclear what advantage, if any, these enzymes confer upon the mainly pathogenic 
organisms that harbour them.  
 
1.4.2.6 Structural analysis of Kinase 
Kinases are a group of enzymes that catalyzes the phosphoryl transfer reaction from a 
phosphor donor (usually ATP) to a receptor substrate. These were classified into 
structure/sequence families with evolutionary implications. Possible biochemical roles 
are suggested by the function of these protein’s homologues. A total of 30 kinase 
families were classified. Of these kinase families, 19 contained at least one member with 
solved structure. These 19 families could be assembled into seven fold groups on the 
basis of similarity of structural fold. Families in the same fold group share structurally 
similar nucleotide-binding domains that are of the same architecture and topography for 
at least the core of domain. Comparative analysis of the protein structural folds allows 
for the inference of biochemical and biological functional properties among kinases 
[Cheek S., et al. 2002]. In the same way that the Type II PanK enzymes were assigned 
to the ribonuclease H-like family, so too were the Type III PanKs. This was based on the 
lack of sequence similarity between the Type I and Type III PanKs as well as their 
dissimilar predicted secondary structure. The absence of solved structure of either the 
Type II or CoaX-like (Type III) Pantothenate kinase does not allow to identify key 
residues through sequence alignments with protein of known structure. Several 
mutational studies carried out by Brand et al. indicate that the placement of the Type III 
PanKs into the ribonuclease H-like fold is justified. By multiple sequence alignment it 
was possible to observe the conservation motif of the ribonuclease H-like families 
between the CoaX and Type II proteins. This multiple sequence alignment helped to 
identify a number of conserved amino acids within the conserved motifs. Specifically 
there were identified key aspartate residues that are putative involved in the binding of 
Mg2+ and a stabilization of the phosphate group of ATP during the course of the PanK 
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reaction, and are based on the known interactions of other ribonuclease H-like proteins. 
A number of aspartate residues are highly conserved in many of sequence compared.  
Aspartate residues corresponding to H. pylori amino acid residues number 17, 87 and 
102 are highly conserved and possibly involved in catalysis. By comparison within the 
ribonuclease H-like family, it is possible identify the presence of conserved aspartate 
residues within the active site of Hp-PanK. These residues are critical for the complete 
functionality of the protein. Mutation to glutamate allows residual activity to remain 
whereas the same mutation to asparagine causes the activity of the protein to decrease 
further. Increasing the substrate concentration does not affect the activity of the mutant 
proteins. 
 
1.4.3 Inhibitors of Type III PanKs 
The research is valuable insofar as the synthesis of new inhibitors  which would be like a 
competitive substrates for the PanK enzymes. As of yet, no inhibitors have been found 
for Type III pantothenate kinases. As many of members belonging to this group are 
pathogenic bacteria and have no alternative pantothenate kinase enzymes in their 
genomes, finding an inhibitor that specifically targets this group and not other type of 
PanK would be invaluable to the formulation of new drugs against these pathogenic 
bacteria.  
Microbes are becoming increasingly resistant to antibiotics. As bacteria evolve new 
means of defying the effects of antibiotics, so it needs the developing of new inhibitors. 
The increasing of bacterial resistance to commonly used antibiotics is of growing 
concern to the healthcare industry. The development and design of new inhibitors would 
go a long way in developing a means to overcome this dilemma. The ideal inhibitor must 
be able to cross the cell membrane and be inhibitory to the pathogenic CoaX proteins 
only. This would truly be a breakthrough in so far as the design of novel inhibitors for 
pathogenic bacteria, such as Helicobacter pylori. New compounds have just been 
designed against the PanK from S. Aureus [Choudhry A.E., et al. 2003]. Their role is the 
blocking of the CoA pathway, compromising the energetic pathogen metabolism. 
Comparison of substrate binding and catalytic sites of PanK-III with that of  PanK-II and 
PanK I, revealed drastic differences in the binding modes for both ATP and 
pantothenate substrates, and suggests that these differences may be exploited in the 
development of  new inhibitors specifically targeting PanK-III isoforms. 
 
 
1.4.4 The role of CoaX proteins 
The role of CoaX in organism that possess another PanK analogue is enigmatic. Does it 
serve as an additional, unregulated form of the enzyme, which is only active under 
certain conditions? Or is it a latent enzyme activity, which has only been adapted to 
PanK activity at a later evolutionary stage? Does the CoaX form of the PanK possess 
unique characteristics that set it apart from the other two types of PanK and in so doing: 
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make it ideally suited for adoption by mainly pathogenic organism for the synthesis of 
Coenzyme A?  
 
1.4.5 Aim of the Project 
This project was carried out by the principal expression, purification and characterization 
methodologies of proteins. In this context we have produced and characterized a 
recombinant HspA. In particular the study has been addressed on the Cys 
oxidised/reduced state, which are present  in the B-domain. To understand how the 
target protein, HspA, can be involved in the redox environment modifications of the 
pathogen H. pylori, we have studied specifically the distribution pattern of disulphide 
bridges. So we have also designed and studied two particular mutants: a single mutant 
Cys94Ala and a double mutant Cys94Ala-Cys111Ala, to investigate on the correct 
disulphide bridge pattern. The disulphide bridge pattern has been assigned by 
integrating classical biochemical methodologies with mass spectrometry. These results 
can be related to the different redox environments that the protein experience inside and 
outside the bacterial cell. Another aim of this project has been the biochemical 
characterization of the Type III PanK from H. pylori; this new type III class posses very 
singular properties and is involved in a critical pathway for pathogen survival: that of 
coenzyme A (CoA) biosynthesis. This enzyme do not share sequence homology with 
any known PanK, and unlike the bacterial and eukaryotic PanK isoforms their activity is 
not regulated by either CoA or acetyl-CoA. They also do not accept the pantothenic acid 
antimetabolite N-pentylpantothenamide as a substrate or are inhibited by it. 
In our study we have cloned the HPCoaX gene and expressed the recombinant protein. 
We have optimized the experimental conditions for purification and stability of the 
expressed protein. The purified protein was analyzed by gel filtration chromatography 
and dynamic light scattering to investigate its state of oligomerization.  
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Chapter II 
Materials and Methods 
 
2.1 Strains, enzymes, reagents and instruments 
Reagents used for preparation of buffers and growth media of Escherichia coli and the 
reagents for polyacrylamide gel electrophoresis (Acrylamide, APS, TEMED, SDS, Tris-
Glycine) were supplied by Sigma Aldrich, Euroclone, Applichem and ICN Biomedicals. 
The molecular weight markers for proteins were from Sigma Aldrich. The restriction 
enzymes and the modification enzymes (calf intestine phosphatase and T4 DNA ligase) 
were supplied by New England Biolabs (NEB) and the molecular weight markers for 
nucleic acids were from NEB and Roche. The Pfu Turbo polymerase (2.5 U/μL) was 
supplied by Stratagene, while Taq DNA polymerase (5 U/μL) was from NEB;  gene 
constructs cloned in  pILL948 were kindly provided by Terradot Laurent (ESRF, 
Grenoble Cedex, France), while pROAEXTc/HpCoaX vector was constructed in our 
laboratory. E. coli TOPF’10 strain, used for cloning,  E. coli BL21(DE3), E. coli 
BL21(DE3)pLysS,  BL21(DE3)STAR competent cells used for screening and 
overexpression and also TEV protease used for recombinant protein cleavage were 
housemade. Complete Protease Inhibitor Cocktail were supplied by Sigma-Aldrich and 
used as a mixture of protease inhibitors, according to manufacturer’s instruction. 
Ethanol, methanol, isopropilic alcohol and acetic acid were supplied by J.T. Baker. The 
protein samples identity were assessed by liquid chromatography mass spectrometry 
(LC-MS) performed on Phenomenex Jupiter C4 and C18 columns, connected to a 
Thermo Electron Corporation mass spectrometer, equipped with an ESI source. Light 
scattering studies were performed on a miniDAWN™ TREOS triple-angle light scattering 
detector, and a Shodex RI-101 refractive index detector, supplied by Wyatt Technology 
Corporation. All size exclusion and affinity chromatography columns were connected to 
AKTA Purifier and FPLC systems (GE-Healthcare).  
 
 
2.2 Antibiotics 
Ampicillin (supplied by Sigma Aldrich as ampicillin sodium salt) and kanamycin (supplied 
by Sigma Aldrich as kanamycin sulphate) were solubilized in deionized water at a 
concentration of 1000X, filter sterilized and stored at –20 °C until use. Ampicillin (Amp) 
was used at a concentration of 100 μg/mL and kanamycin (Kan) was used at a 
concentration of 50 μg/mL in both solid and liquid media. Chloramphenicol (CAM) and 
tetracycline were solubilized in ethanol 95% and used at a concentration of 33 μg/mL 
and 12.5 μg/mL, respectively. 
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2.3 E. coli cells transformation techniques  
2.3.1 Preparation of E. coli TOPF’10 cells and transformation by electroporation  
About 2.5 mL of an overnight culture of E. coli TOPF’10 cells were inoculated into 250 
mL of LB medium. The cells were grown up to mid-log phase (OD600 ~ 0.6) at 37 °C, 
stored on ice for 30 min and then harvested by centrifugation (6000 rpm, 10 min, 4 °C). 
The pellet was washed in 250 mL of sterile water. After the second centrifugation the 
cells were washed in 125 mL of sterile water. The third washing was performed in 5 mL 
10% glycerol; the cells were then harvested by centrifugation and the pellet was 
resuspended in 750 μL of 10% glycerol. Aliquots of 1010 cells/mL (40 μL) were mixed 
with 1 μL of the DNA ligase reaction, incubated for 1 min on ice and transferred into 
chilled plastic cuvettes with an electrode gap of 0.2 cm (M-Medical). High voltage 
electroporation (25 μF) was performed with a Bio-Rad Gene Pulser XcellTM at a field 
strength of 2.5 kV/cm and 200 Ohm. A shock pulse was applied to competent cells 
producing pulse length of ~5.0-5.5 ms. Immediately after electroporation cell mixtures 
were diluted to 1 mL with LB medium and incubated for ~1 h at 37 °C under shaking. 
The cells were then plated onto selective solid medium supplemented with appropriate 
antibiotic to isolate the recombinant clones. Single clones were inoculated in 5 mL LB 
medium with the same antibiotics and grown over night at 37 °C under shaking. Finally, 
were harvested by centrifugation (13000 rpm, 2 min, 4 °C) and processed to extract 
plasmidic DNA by using the QIAprep Spin Miniprep Kit or the QIAGEN plasmid Maxi Kit 
(both supplied by Qiagen).  
 
 
2.3.2  Preparation of E. coli competent cells and transformation by heat shock  
Single clones of E. coli strains, grown at 37 °C in LB agar, were inoculated into 2.5 mL 
of LB medium and incubated overnight at 37 °C on a shaker. The cells were inoculated 
into 250 mL of LB medium and the culture was grown up to mid-log phase (0.6 
OD600nm) at 37 °C, stored on ice for 30 min and then harvested by centrifugation (6000 
rpm, 10 min, 4 °C). The pellet was washed in 125 mL of cold 50 mM CaCl2 and stored 
on ice for 30 min. Successively, the cells were harvested by centrifugation and the pellet 
resuspended in 16 mL of cold 50 mM CaCl2. Aliquots of 200 μL of competent cells were 
mixed with 50 ng of plasmidic DNA target and stored on ice for 30 min. The cells 
mixtures were transferred at 42 °C for 2 min, on ice for 2 min (heat shock) and then 
diluted to 1 mL with LB medium. An incubation of 1 h at 37 °C under shaking was 
performed before plating the cells onto selective solid medium supplemented with the 
opportune antibiotics, depending on the strain. 
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2.4 Expression in E. coli of HspA wild type, Cys94Ala and Cys94Ala-Cys111Ala, 
and HpCoax 
2.4.1 Cloning of different constructs  
Genes were amplified by PCR from genomic DNA. The amplification was performed by 
using the specific couples of primers. All amplification reactions were performed in a 
final volume of 50 μL, using 50 ng of template DNA. The reaction mixture contained the 
specific primers (0.25 μM each), dNTPs (0.25 mM each), 10x amplification buffer, 
MgSO4 (25mM), and the Pfu turbo polymerase (5U) with its buffer. PCR reaction was 
performed using an Eppendorf Mastercycler personal apparatus, following the 
procedure indicated below: 
 
 Initial denaturation (step 1)                      3 min at 95 °C  
 Denaturation (step 2)                               1 min at 95 °C  
 Annealing (step 3)                                   1 min at the convenient        
                                                                 temperature for each gene amplified  
 Elongation (step 4)                                  1 min at 72 °C  for 30 cycles, from step 2 
 Elongation (step 5)                                  10 min at 72 °C  
 
All amplification products were analyzed by 0.8%  agarose (Euroclone) gel 
electrophoresis performed in TAE buffer (18.6 g/L EDTA, 242 g/L Tris base. Add Acetic 
acid until pH 7.8). PCR products were purified by using the QIAquick PCR Purification 
Kit (Qiagen), and digested with restriction enzymes. Each amplified fragment (1μg) was 
digested with 4 U of restriction enzymes for 3 h at 37 ºC in a buffer containing 50 mM 
NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT pH 7.9 supplemented with BSA 100 
μg/mL. Following the digestion, each fragment was cloned into the corresponding sites 
of the pETM11 expression vector (for HspA) and pPROEX-HTc expression vector (for 
HpCoaX) downstream to the His-tag sequence. To this purpose, the expression vector 
was previously digested with the same restriction enzymes (4 U/μg), and treated with 
calf intestine phosphatase (CIP, 10 U) (NEB) for 30 min at 37 ºC. CIP enzyme (10 U/μL) 
was then inactivated at 75 °C for 10 min. After digestion, PCR amplifications were 
purified by QIAquick PCR Purification Kit, while the digested pETM11 was purified by 
QIAquick Gel Extraction Kit (Qiagen). In order to determine the concentration of the 
digested plasmid and PCR products, 5µl of each were run on a gel. They were run 
against the ladders containing bands of known concentration. By comparing the intensity 
of the DNA sample with that of the ladder it is possible to determine the concentration of 
the DNA sample in ng/µl. This value is converted to fmoles/µl for the purpose of the 
ligation reaction. The concentration of the digested plasmid is not always equal to that of 
the digested PCR product. For ligation reactions was used a 1:3 molar ratio 
(vector/insert DNA). The reactions were performed using the Quick LigationTM  Kit. This 
kit ensures that the entire ligation protocol is completed in 5 minutes and is highly 
reliable: 20 U/μg DNA of the T4 DNA Ligase (400 U/μL), in a final volume of 10 μL, for 3 
h at RT. The products of the ligation reaction were transformed into E. coli TOPF’10 
strain electrocompetent cells. The transformation procedure is carried out by 
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electroporation. Thereafter 1mL of LB is added to the transformation mixture and it is 
incubated in a shaking incubator (200 rpm) for 1h at 37°C. The cell pellet is collected by 
centrifugation at 8000 rpm for 5 minutes. Using a pipette 800 µl of the supernatant is 
removed (being careful not to disturb the cell pellet) and the cells are then re-suspended 
in the remaining media. This is plated onto LB agar plate containing the relevant 
antibiotic. The cells are spread evenly on the plate by means of sterile glass pasteur. 
The plate is incubated at 37°C overnight. A screening is conducted to check for the 
insertion of the gene of interest into the plasmid. Firstly, a screening agarose gel is run. 
From the results of the screening gel, colonies are chosen and plasmids prepared from 
these colonies. Then, these plasmids are digested with the original restriction enzymes 
to check for an insert of the correct size. So, using a sterile toothpick, a single colony is 
scraped from the LB plate and re-suspended in a lysis solution (30 mM Tris pH 8.0, 5 
mM Na2EDTA, 50 mM NaCl, 20% sucrose, 0.05 mg/ml lysozime and 0.05 mg/ml 
RNAse). The process is repeated for each colony. The tubes are vortexed briefly 
followed by addition of 10µl of a second solution containing 1x TAE, 2% SDS, 5% 
sucrose and 2 mg/ml bromophenol blue. Then 10µl of the mixture from each tube is 
loaded on a 1% agarose gel. We can loaded an undigested pETM11 as a standard. The 
gel run at about 80V. Positive screens are those that are bigger than the plasmid 
standard loaded  as a marker. A representative of the positive screens is used to 
inoculate 5 ml of media with the relevant antibiotic and grown in a shaking incubator at 
37°C overnight. The above overnight culture is used to purify a plasmid and to make a 
Mini preparation of DNA. This is done with the help of the Quiagen Miniprep Kit. The 
purified plasmid is digested with the original restriction enzyme used to cut it before 
ligation reaction. The digestion products are run on a 1% agarose gel against the 
ladders. Positives clones are those that produce inserts the size of the gene of interest. 
The identity of the inserts in the resulting recombinant plasmids was confirmed by DNA 
automated sequencing (suppling by Sbm). On confirmation the clones are stocked at -
20°C. After, positive plasmid is transformed  into a appropriate E. coli strain cells for 
expression. (The best E. coli strain for each construct is chosen after an accurate 
screening of expression). For the cloning of HspA wt , HspA single mutant Cys94Ala 
and HspA double mutant Cys94Ala-Cys111Ala we have used pETM11 expression 
vector, while for HpCoaX we have used pPROEX-HTc expression vector. 
 
2.4.2  Expression vector properties 
 
Expression systems are designed to produce many copies of a desired protein within a 
host cell. In order to accomplish this, an expression vector is inserted into a host cell. 
This vector contains all of the genetic coding necessary to produce the protein, including 
a promoter appropriate to the host cell, a sequence which terminates transcription, and 
a sequence which codes for ribosome binding. One expression system was developed 
in 1986 by W. F. Studier and B. A. Moffatt, who created an RNA polymerase expression 
system which was highly selective for bacteriophage T7 RNA polymerase. The initial 
system involved two different methods of maintaining T7 RNA polymerase into the cell - 
in one method, a lambda bacteriophage was used to insert the gene which codes for T7 
RNA polymerase, and in the other, the gene for T7 RNA polymerase was inserted into 
the host chromosome (Studier et al, 1986). This expression system has become known 
43 
 
as the pET Expression System, and is now widely used because of its ability to mass-
produce proteins, the specificity involved in the T7 promoter which only binds T7 RNA 
polymerase, and also the design of the system which allows for the easy manipulation of 
how much of the desired protein is expressed and when that expression occurs. The 
pET System is the most powerful system yet developed for the cloning and expression 
of recombinant proteins in E. coli. The pET plasmids were chosen as they represent a 
powerful host-vector system for cloning and expression of recombinant proteins in E. 
coli. All of them contain a strong promoter from T7 bacteriophage, for chemical induction 
and overexpression of recombinant proteins, a multiple cloning site (MCS) and a TEV 
protease recognition site for cleaving the fusion protein (Fig. 2.1). Control of the pET 
expression system is accomplished through the lac promoter and operator. Before YFG 
can be transcribed, T7 polymerase must be present. The gene on the host cell 
chromosome usually has an inducible promoter which is activated by IPTG. This 
molecule, IPTG, displaces the repressor from the lac operator. Expression is induced by 
the addition of IPTG or lactose to the bacterial culture or using an autoinduction medium 
[Elvin C.S. et al. 1990], [Terpe, K. 2006]. 
In particular, pETM11 contains only a His6-tag while to improve the solubility of the gene 
products (Fig. 2.2). The expression vector pPROAX-HTc  is a bacterial plasmid which 
carries a Trc promoter, a His6 protein tag at the N-terminous, and an  Ampicillin 
resistance.( Fig. 2.3) 
 
 
 
 
Fig. 2.1: General scheme of the gene expression regulation by the insertion into pET system 
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Fig. 2.2: Map of expression vector pETM11. 
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Fig. 2.3: Map of expression vector of pROEX-HTc vector 
 
 
2.4.3 Scale up expression  
Because of the vast fund of knowledge about its genetics, biochemistry, and molecular 
biology, Escherichia coli is the system of first choice for expression of many 
heterologous proteins. Genetic manipulations are straightforward, cultures of E. coli are 
easily and inexpensively grown, and many foreign proteins are well-tolerated and may 
be expressed at high levels [Sambrook and Russel, 2001]. E. coli expression systems 
can be used for the production of recombinant proteins either intracellularly or 
extracellularly. Recombinant expression plasmids require a strong transcriptional 
promoter to control high-level gene expression. 
 
2.4.3.1 Expression of HspA and HpCoaX from H. pylori 
The gene encoding HspA (hp0011) was inserted into the pETM11a expression vector 
(Novagen) to give pILL948 as described (Kansau et al., 1996). Single (C94A) and 
double (C94A/C111A) HspA mutants were constructed using the QuickChange site 
directed mutagenesis protocol (Stratagene). The vector was introduced into the E. coli 
BL21(DE3)pLysS expression strain (Invitrogen) using heat-shock: 1ul of vector (50 
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ng/ul) was added to 100ul of cells. After a first screening of small-scale expression 
cultures, performed using different strains, temperatures, IPTG concentration and 
induction length, recombinant constructs were transferred into E. coli strain that assured 
the best expression level in soluble phase. The transformed cells were transferred on 
LB-Agar plates ( 15 g/L Agar, 10g/L NaCl, 10g/L Tryptone, 5g/L Yeast extract) 
supplemented with antibiotics (100ug/mL Ampicillin, 50ug/mL Cloramphenicol) and 
incubated overnight at 37°C. This pre-culture was then used to inoculate 10mL of fresh 
LB broth (Luria-Bertani growth medium: 10g/L NaCl, 10g/L Tryptone, 5g/L Yeast extract) 
supplemented with antibiotics (100ug/mL Ampicillin, 50ug/mL Cloramphenicol), using 
selected single colonies from LB-Agar plates. The cultures were then incubated 
overnight at 37°C. For protein preparation, 1L of pre-warmed LB medium supplemented 
with 100 mg/l ampicillin and 50 mg/l chloramphenicol was inoculated with 10mL of pre-
inoculum described above and the resulting culture was grown at 37°C. When the OD600 
reached 0.5-0.6, expression of recombinant protein was induced by the addition of 
isopropyl-d-thiogalactopyranoside (IPTG) to 1 mM final concentration and cells were 
incubated  at 22° or 37 °C as appropriate. After 3 or 16 h (if we work at the overnight 
induction) the solubility of each protein was assessed by harvesting the cells 
(centrifugation at 6000 rpm, 15 min, 4 °C). Cell pellets were resuspended in a lysis 
buffer appropriate and optimized for each target protein studied. For HspA and its 
mutants the lysis buffer containing 0.02M Na2HPO4, 0.5M NaCl, 1mM  MgCl2 , pH 7.4 
and protease inhibitors. While HpCoaX cell pellets were resuspended in a very accurate 
buffer contains 50mM TRIS pH 8.0, 500 mM NaCl, 5% Glycerol, 0.2 % TRITON X_100, 
2mM DTT, PMSF, Lysozime, DNase, Protease Inhibitors , 10mM Imidazole. The 
suspension was sonicated for about 10 min (time depends on the lysate volume), by 
using a Misonix Sonicator 3000 apparatus with a micro tip probe and an impulse output 
of 1.5/2 (=9/12 Watt). Bacterial lysates were then centrifuged (16000 rpm, 30 min, 4 °C) 
and the supernatant (soluble fraction) was collected and analyzed by SDS-PAGE to 
assess the presence of recombinant products of interest.  
 
2.4.3.2 Construction of expression vector of Type III Pank from H. pylori (HpCoaX) 
The H. pylori HpCoaX gene (HP0862) was amplified by PCR from H. pylori genomic 
Dna using Taq DNA polymerase and the following primers: 5’-
ATAAGAAGTAGGCATATGCCAGCTAGGC-3’ (forward primer), introducing an NdeI site 
(underlined) at the start of the gene, and 5’-ATGCCCAAAAAACTCGAGTTGTGCATC-3’ 
(reverse primer), introducing an XhoI site (underlined) at the end of the gene. The 
resulting PCR products were digested with NcoI and XhoI  and ligated to NcoI/XhoI-
digested pROAEXTc expression vector using the NEB Quick Ligation Kit.  The 
sequence of the resulting plasmid, was verified by automated DNA sequencing. 
HpCoaX protein was prepared by cloning the target gene into overexpression vector 
coding for N-terminal His6-tagged fusion protein. The vector was transformed into 
BL21(DE3)pLysS; culture was grown at 37°C to an A600 of about 0.6, and subsequently 
induced by the addition of IPTG. After growing overnight at 37°C, the cells were 
harvested, suspended in sonication buffer, disrupted by sonication and centrifuged at 
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15.000x g for 30 min to clarify the cell-free exstract. The protein was overexpressed and 
purified using immobilized metal affinity chromatography. 
 
2.4.4 Purification of 6xHis tagged proteins 
 
Lysates containing tagged recombinant proteins were purified by affinity 
chromatography onto HisTrap columns connected to an AKTA-FPLC system. Before 
loading the lysate, the resin was extensively washed with water and then equilibrated in 
buffer A (20 mM Na2HPO4, pH 7.4, 500 mM NaCl, for HspA; and 50mM TRIS pH=8, 
500mM NaCl, 10mM Imidazole, for HpCoax). The lysate was loaded in presence of 10 
mM imidazole to avoid non-specific binding of E. coli contaminants. Flow-through 
containing all unbound proteins was collected and the resin was washed with buffer A; 
finally His-tagged proteins were eluted with high concentrations of Imidazole (250-300 
mM) applying a gradient 0-100% of eluition buffer B (buffer A and 500mM Imidazole). All 
collected pools (flow-through, washes and elutions fractions) were analyzed on SDS–
PAGE gels and stained with Coomassie Brilliant Blue R-250. Pools of interest were 
dialyzed to remove Imidazole by using Spectra/Por membranes with the appropriate 
MWCO. The purity and homogeneity was tested by SDS-PAGE and by mass 
spectrometry. Antigenicity of the recombinant proteins was analyzed by western blot. 
 
2.4.5 TEV digestion of tagged proteins  
 
TEV protease is a very useful reagent for cleaving fusion proteins. It is also relatively 
easy to overproduce and purify large quantities of the enzyme. After purification by 
affinity chromatography, all partner-tagged proteins were dialyzed overnight against TEV 
buffer (50 mM Tris/HCl, 500 mM NaCl, 5mM EDTA, 1mM DTT, pH 8.0) at 4 °C. TEV 
protease was added to protein substrates, using a molar ratio (protease : substrate) of 1 
: 50. Cleavage products were analyzed by polyacrylamide gel electrophoresis; then, 
mixture was loaded onto an HisTrap column and purification was performed in the same 
conditions described above: protein product of interest was eluted in flow-through, while 
the fusion partner and un-cut complexes were bound to resin and removed with 
imidazole.  
 
2.4.6 Size Exclusion Chromatography 
A gel filtration column separates proteins based on their size and shape. A gel filtration 
column is packed with a gel which comprises porous beads, e.g. highly cross-linked 
agarose. When a sample is passed down the column, separation depends on the 
different abilities of the sample components to enter the pores within the gel beads. 
Larger molecules, which cannot enter even the largest pores, pass through the column 
fastest. Smaller molecules, which can enter the pores freely, are delayed to different 
degree during the passage through the gel, depending on their size and shape. Proteins 
are therefore eluted in order of decreasing size. The advantages of gel filtration are that 
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the method is easy to use, it provides free choice of eluent, works almost always, and 
the result is easy to predict. Due to limitations such as low resolution and small sample 
volume, this chromatography technique is preferably used as an intermediate, or final 
purification step. Also, it should be noted that influence of flow rate, and column 
efficiency, plays important roles. Size exclusion chromatography was performed to purify 
all recombinant proteins previously expressed and produced in E. coli strains,  by 
removing aggregates and contaminants. Runs were carried-out at a flow of 0.5 ml/min 
onto a Superdex _200 [10/30] (Amersham Biosciences) and Superdex-75 [10/30] 
columns connected to an AKTA Purifier system, in 20mM TRIS pH 7.4, 200mM NaCl. 
Molecular weight standards from GE-Healthcare were used to calibrate column. A 
calibration curve is prepared by measuring the elution volumes of several standards, 
calculating their corresponding Kav values and plotting their Kav values versus the 
logarithm of their molecular weight. The molecular weight of a protein is determined from 
the calibration curve once its Kav value is calculated from its measured elution volume.  
 
where Ve is the elution volume for the protein, V0 is the column void volume (elution 
volume for Blue Dextran 2000) and Vt is the total bed volume. Pools of interest were 
concentrated on Amicon-Ultra membranes 5k (Millipore) and on Centriplus centrifugal 
filter (Millipore). Aliquots of purified proteins were stored at -80°C. 
 
2.4.7 Light scattering analysis (SEC-MALS) 
The MW of protein can also be determined by analytical size exclusion chromatography 
combined with multi-angle light scattering (SEC-MALS). To perform the SEC-MALS 
analysis we have used a SEC-LS system consisting of a semi-preparative size exclusion 
chromatography column (Superdex-200 10/30, GEHealthcare) coupled to a light 
scattering detector (miniDAWN TREOS) and a differential refractive index detector 
(Shodex RI-101).  
The Astra (5.3.4 version, Wyatt Technology Corporation) software allowed us to the 
collect, record, and process the scattering data. Data is processed assuming a specific 
refractive index increment (dn/dc) of 0.185 ml/g. To determine the detector delay 
volumes and the normalization coefficients for the MALS detector, a BSA sample 
(Sigma) is used as a reference. 
 
2.5 Protein Analyses  
2.5.1  Determination of the protein concentration  
The concentration of the proteins in solution was determined according to the Bradford’s 
method (Bradford, 1976). The Coomassie Brilliant (Bio-Rad) reagent was added to the 
samples and the absorbance at 595nm was monitored. A solution of bovine serum 
albumin (BSA) was used as standard. Protein concentration was also measured by UV 
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spectroscopy, reading the absorbance at 280nm. The protein concentration value is 
obtained applying the Lambert-beer law and knowing the specific ellipticity coefficient 
(ε). The measure is carry out using a Jasco V-550 UV-VIS spectrophotometer, in a 1 cm 
quartz cell.  
 
2.5.2 Electrophoretic analysis of proteins (SDS-PAGE)  
SDS-polyacrilamide gels determined the purity of the proteins (Fig. 2.4). The gel 
consists of a running gel (40% v/v 30% acryl-bisacrylamide mix, 0.75M Tris pH 8.8, 
0.1%SDS v/v, 0.1% APS v/v and 0.04% TEMED v/v) and a stacking gel (17% v/v 30% 
acryl-bisacrylamide mix, 0.063M Tris pH 6.8, 1%SDS v/v, 1% APS v/v and 0.33% 
TEMED v/v). The electrophoresis on 12% or 15% polyacrylamide gel in denaturing 
conditions was performed according to Laemmli’s protocol (Laemmli, 1970). The 
samples were denatured in the heating block at 95°C for 5 min and pre-treated  with 
loading buffer: 1% SDS (Applichem), 5% β-mercaptoethanol (Sigma), 0.001% 
bromophenol blue (ICN Biomedicals) and 10% glycerol (Applichem). The samples were 
then loaded on a polyacrylamide gel and the electrophoresis was performed in 0.025 M 
Tris/HCl, 0.2 M glycine pH 8.3 and 0.1% SDS, at 30 mA until the front of the samples 
reached the bottom of the gel . The proteins were then revealed by Coomassie Brilliant-
Blue (Applichem) staining; the gel was submerged in the staining solution (0.1% 
Coomassie Brilliant-Blue R250, 25% isopropilic alcohol and 10% acetic acid) for 30 min 
with gentle agitation. The gel was washed in a solution containing 30% ethanol and 10% 
acetic acid to remove the excess of Coomassie and then washed again in deionized 
water for 2 times for 10 min each. Alternatively, the proteins were transferred by 
electroblotting from gel to a polyvinylidene fluoride (PVDF) membrane as described in 
the paragraph “Western blot analysis”.  
 
 
 
Fig. 2.4: SDS effect on the protein conformation 
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2.5.3  Western Blot analysis  
After gel electrophoresis, proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane (BioRad) in Washing Buffer (25 mM Tris/HCl pH 8.0, 190 mM Glycine and 
10% methilic alcohol). The PVDF membrane was submerged in methilic alcohol for 2 
min before using, to eliminate the hydrophobic properties, washed in H2O for 2 min and 
equilibrated in Washing Buffer for 5 min. After the electro-blotting using a powerfully 
system (BioRad), membrane was stained with Ponceau Red to verify proteins 
transferring and incubated in the blocking solution (0.5% NFDM in TTBS buffer, 
containing 0.05% Tween 20) at room temperature for 1 h. It was washed with TTBS 
buffer, and after incubated in a mouse anti-His peroxidase-conjugated anti-mouse 
antibody (Sigma Aldrich) 1:1000 dilution, at room temperature for 1 h. Membrane was 
finally washed with TTBS buffer. The detection of immunopositive species by enzyme-
linked chemi-luminescence (enhanced chemi-luminescence: ECL) was performed 
according to the manufacturer’s instructions, using a specific detection kit (Bio-Rad).  
 
2.5.4  Mass spectrometry 
LC-MS, using a Phenomenex Jupiter C18 column (4.6 x 250 mm, 5 μm, 300Å), was 
performed to confirm the mass of HspA wt, its mutants and of HpCoax. The method 
developed at 1 mL/min with a linear gradient of 0.05% TFA in H2O (buffer A) in 0.05% 
TFA in CH3CN, from 5% to 70% for 30 min.  
 
2.5.4.1  Vinyl pyridine assay (4-VP) 
The 4-Vinyl-pyridine assay was performed using specific reagent and monitoring the 
reaction by mass spectrometry. At the first the sample was treated with a denaturing 
buffer; after it was incubated with the 4-VP; the reaction of alkylation was carried out in a 
thermo-block, at the temperature of about 65°C. The samples were analyzed by LC/MS.  
 
2.5.5  Cys distribution in GroES proteins 
The search was carried out against all sequences in the non redundant database 
RefSeq (www.ncbi.nlm.nih.gov). The database was accessed in February, 2007. The 
keyword GroES in the Gene Name field restricted to master sequences (master of set of 
segmented sequences) resulted in 313 hits; 4 sequences consisting of a residue 
number less than 50 or greater than 220 were discarded; the 3 HspA sequences from 
HELPY, HELPJ, HELAC were also discarded. The working subset of GroES sequences 
contained 306 sequences consisting of  30145  residues in total. The search for Cys 
residue revealed only 14 cysteines in 13 sequences. For comparison the frequency of all 
20 naturally occurring aminoacids was computed;  the most abundant amino acid is 
valin with 3603 residues (12.0%) whereas the less represented – apart from Cys – is 
tryptophan, with 66 residues (0.2%), as expected. A query in the PDB database for the 
3D-structure of any of the 13 Cys-containing sequences resulted in 0 hits, so the 3D-
structure is unknown. 
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2.5.5.1 Chemical modification of cysteine residues 
Reduction of Cys residues in HspA was carried out in 0.25 M Tris-HCl, 1.25 mM EDTA, 
pH 8.0 containing 6 M guanidinium chloride by incubation with a 10:1 molar excess of 
dithiothreitol (DTT) over the total -SH groups at 37°C for two hours under nitrogen 
atmosphere (N2 flow). Alkylation of native HspA was performed by incubation of the 
protein in tha same buffer with a 10-fold molar excess of iodoacetamide (IAM) over the 
total -SH groups for 10 min at room temperature in the dark. For reduction and 
carboxyamidomethylation of the Cys residues, HspA was incubated with a 10:1 molar 
excess of DTT over the total -SH groups at 37°C for two hours under nitrogen 
atmosphere followed by alkylation with a 10-fold molar excess of iodoacetamide over 
the total -SH groups for 10 min at room temperature in the dark. In all cases, the protein 
samples were desalted by reverse phase chromatography (RP-HPLC) on a C-4 column 
using a HP 1100 chromatograph (Agilent Technologies). The elution was performed with 
a speed gradient of 0.1% TFA (buffer A) and 0.07% TFA in 95% acetonitrile (buffer B). 
HPLC-desalted HspA samples were directly analysed by ES/MS using a Quattro Micro 
triple quadrupole mass spectrometer (Waters). Data were recorded and after analyzed 
by the Mass Lynx. Software. 
 
2.5.5.2 Mass spectrometry measurements 
HPLC-desalted HspA samples were directly analysed by ES/MS using a Quattro Micro 
triple quadrupole mass spectrometer (Waters). Samples were injected into the ion 
source by a Harward syringe pump at a flow rate of 10 l/min. Data were acquired and 
processed by the Mass Lynx software provided by the manufacturer. The instrument 
was calibrated by a separate injection of horse heart myoglobin (average molecular 
mass 16,951.5 Da); all masses are reported as average mass.  
 
2.5.5.3 Enzymatic Hydrolysis 
Native HspA was digested with trypsin in 50 mM ammonium acetate, pH 6.0 at 37°C 
overnight, using an enzyme/substrate ratio of 1:50 (by mass). The mixtures of tryptic 
peptides were either directly analyzed by MALDI mass spectrometry using a Voyager 
DE PRO instrument (Applied Biosystem). 
 
2.5.5.4 Analysis by MALDI mass spectrometry  (MALDI/MS) 
Mass mapping experiments were performed by MALDI mass spectrometry analysis 
using a Voyager DE PRO instrument (Applied Biosystem) operating both in linear and 
reflectron mode. Typically, 1 µl of analyte solution was mixed with 1 µl of a-cyano-4-
hydroxycinammic acid 10 mg/ml in acetonitrile/50 mM ammonium citrate, 70:30 v/v, 
containing 250 fmol of bovine insulin. The mixture was applied onto the metallic sample 
plate and air dried. Mass calibration was performed using the quasi-molecular ions of 
insulin at m/z 5734.5 and a matrix peak at m/z 379.1 in linear mode and by multipoint 
calibration in reflectron mode using a peptide calibration mixture provided by the 
manufacturer. All mass values in linear mode are reported as average masses, whereas 
those measured in reflectron mode are reported as monoisotopic values. 
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2.5.6 Disulphide bridges pattern 
The  protein dilsuphides bridge pattern assessment can be carried out by mass 
spectrometry techniques. The peptidic mix obtained by enzymatic hydrolysis has been 
analyzed to minimize the possibility of dilsuphide bridge reduction and arrangement. 
Protein hydrolysis can isolate each cysteine into a different peptide to facilitate the data 
interpretation. Mass spectra signals are been attributed at specific peptides basing on 
their molecular weight. It is possible to individuate specific signals from two peptides 
linked by a disulphide bridge, and consequently the cysteine residues involved in the S-
S bond. The assessment is confirmed treating the mix with a reducing agent and 
analyzing it again by MALDI/MS. The signals from peptides linked by disulphides 
bridges disappear to generate higher mass values corresponding to reduced peptides. 
The assessment of distribution disulphides bridges pattern in HspA wt and its mutants is 
been executed essentially by enzymatic digestion and then by MALDI/MS analysis on 
the peptidic mix, according to the well established mass-mapping strategy [Amoresano 
A., and Pucci P., 2003], [Amoresano A., and Pucci P., 2001], [Morris H.R., and Pucci P., 
1985]. This provides to define a peptidic map of a protein: specific signals are attributed 
basing on the peptides molecular mass and on the specific proteolytic enzymes used. 
 
2.5.7 Modelling of HspA 
The structure of the A domain of HspA was generated by homology modelling using the 
automatic modelling Swiss Modeller server using Escherichia coli GroES as a template 
(pdb code 1wnr.pdb) Ref). Three models were generated and validated using verify 3D 
(refs). In addition, the loop consisting of residue 50-53 was rebuilt and minimized to fit 
the biochemical data obtained in the study (disulphide bridge between Cys51 and 
Cys53). To illustrate the results obtained in our study (disulphide bridge pattern) we 
added the B domain to the A domain by manual building in COOT [Emsley P., Cowtan 
K., 2004]. Minimization was carried out using GROMOS96 implementation of Swiss-
PdbViewer [van Gunsteren et al., 1996].  
 
2.5.8 Circular dicroism analysis (CD) 
All CD spectra were recorded with a Jasco J-810 spectropolarimeter equipped with a 
Peltier temperature control system (Model PTC-423-S) in a 0.1 mm quartz cell. The 
spectropolarimeter was calibrated with an aqueous solution of 1S-(+)-10-
camphorsulfonic acid at 290 nm. Molar ellipticity per mean residue, [ ] in degrees cm2 
dmol-1, was calculated from the equation: [ ] = [ ]obsmrw(10lC)-1, where [ ]obs is the 
ellipticity measured in degrees, mrw is the mean residue molecular mass (111.5 Da), C 
is the protein concentration in g L-1, and l is the optical path length of the cell in 
centimeters. Spectra were acquired according the following parameters: far UV range of 
190-260nm, band width of 1nm, response of 8 sec, data pitch of 0.2nm and scanning 
speed of 10 nm/min. Spectra were carried out at 20 C using a 0.01 cm optical path-
length cell and a protein concentration of 10-15 mg mL-1. Cuvettes with path lengths of 
0.2 and 0.5 cm and protein concentrations of 0.2 and 0.8 mg/mL were used in the far-
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UV and near-UV regions, respectively. CD spectra were recorded with a time constant 
of 4 s, a 2 nm bandwidth, and a scan rate of 5 nm/min, and were signal-averaged over 
at least three scans, and baseline corrected by subtracting a buffer spectrum. Thermal 
unfolding curves were recorded in the temperature mode, over the range of 5-110 C, 
with a scan rate of 1.0 C/min. Samples were rapidly cooled after the first heating run 
and scanned for a second time to estimate the reversibility of the unfolding transition. CD 
data were expressed as mean residue ellipticity (). Spectra processing was obtained by 
using the Spectra Manager software. Proteins concentrations was determined by 
monitoring Tyr absorbance at 278nm and using the molar extinction coefficient derived 
by the calcule from ProtParaM tool (By expasy database). CD intensity is expressed as 
mean residue ellipticity (deg ×cm2×dmol−1 of amino acid) calculated referring to the 
total amino acid concentration.  
 
2.5.9 Crystallization tests 
Protein samples of HpCoaX were concentrated to 12 mg/mL, in 20 mM Tris/HCl pH 8.0 
150 mM NaCl, 3 mM DTT using Centriplus centrifugal filter (Millipore). Protein 
concentration was estimated by the method of Bradford, using BSA as standard 
(Bradford, 1976). Crystallization experiments were carried out at 20 °C, and at 4°C,  
using the hanging and/or sitting-drop vapour-diffusion technique. Initial crystallization 
conditions were found using commercially available crystallization-screening kits (Crystal 
Screen I and II, INDEX I and II, Hampton Research, Riverside, CA). Drops containing 
equal volumes (1 μL) of protein and reservoir solution were equilibrated against 1 mL of 
reservoir solution. Several crystal forms were obtained only at 4°C, using a reservoir 
solution containing 0.1 M Bis-Tris pH 6.5, 0.2 M. Only diffraction data at low resolution 
were obtained from these crystals (about 5 Å). Several parameters such as 
crystallization technique, buffer composition, protein concentration and ionic strength 
were varied in order to improve the quality of the crystals. We have also carried out 
some co-crystallization experiments, or soaking, using  nonhydrolysable analogue of 
ATP (AMPPNP), and substrate (PAN), in the presence of MgCl2. Unlikely we did not 
observe an improving of crystal’s quality. 
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Chapter III 
Results and discussion 
3.1 Expression and purification of HspA 
In order to obtain and characterize the HspA we have produced this protein by recombinant 
strategy. The gene encoding HpHspA (hp0011) was inserted into the pETM11a expression 
vector. To analyze cysteine residues located on B-domain we have also expressed two 
mutant variants of HspA: Cys94Ala (single mutant) and Cys94Ala, Cys111Ala (double 
mutant). The strain BL21(DE3) pLysS was chosen for the optimal expression that was carried 
out at 22 °C for 16 h. as described before (see 2.4.3.1 section). The expression was 
assessed by SDS-PAGE, running the samples before and after the induction (Fig. 3.1). HspA 
possess a natural His8-tag at the C- terminus, which can be used for the purification affinity 
steps. Following induction with IPTG, all recombinant proteins were purified from E. coli 
whole-cell extracts by affinity chromatography, loading them onto nitrilo-tri-acetic acid-
chelating nickel (Ni-NTA) columns, frequently used to purify recombinant histidine-rich 
proteins. This first step of purification is showed in figures 3.2 and 3.3. HspA-wt and its 
mutants bound to the Ni-NTA resin and, following elution, exhibited the expected molecular 
weights (13 kDa) as visualized by SDS-PAGE analysis (Fig. 3.4). 
 
 
 
Fig. 3.1: SDS-PAGE before the IPTG induction, after 3h and 4h 
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Fig. 3.2: His-trap profile of HspA wt 
 
 
 
 
Fig. 3.3: His-trap profile of HspA double mutant 
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       Fig. 3.4: SDS-page analysis after His-trap affinity. Gel on the left shows different fractions eluted: Cell     
extract (G1,G2), Flow trough (Ft1, Ft2),single mutant (sm) and double mutant (dm1, dm2). Gel on the right 
shows HspA wt fractions. 
 
After, we have carried out exclusion chromatography assay (gel filtration); the relative profiles 
are reported in figures 3.5 and 3.6. Gel filtration analysis was also conducted in the presence 
of DTT. HspA was treated with the reducing agent, and then it was loaded on Superdex_200 
column. The multimeric rate decreses significantly and the protein can be eluted as a 
heptameric form. The formation of aggregates is time dependent and is strongly dependent 
on the cysteines oxidation (Fig. 3.7). 
 
 
 
                                                               Fig. 3.5: Gel Filtration profile SDS-Page analysis of HspA wt. 
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  Fig. 3.6: Gel filtration profiles of two mutants: the wt and Cys94Ala show the same 
 profile while the Cys94Ala/Cys111Ala presents a single peak 
 
 
 
Fig. 3.7: Gel Filtration profile of HspA wt stored at 4°C for two days. In red is showed the 
           first injection on Superdex_200, in blue the second injection, after about 1h. 
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3.1.2 Gel filtration analysis in presence of Ni2+ and Bi3+ 
The HspA wt was first incubated with TCEP (24 equivalents) for about 1h. Then the samples 
were treated for about 30 minutes  with a buffer containing NiSO4 1mM and Bi(NO3)3 5mM 
respectively and loaded onto a Superdex_75 column. The profile in the presence of these 
metals shows only one peak in both cases (Fig. 3.8). The resulting protein is concentrated 
and then used for crystallization experiments. Unfortunately the drops did not show the 
presence of any crystals. 
 
 
 
Fig. 3.8: Gel filtration profiles of HspA with nickel and bismuth 
 
 
3.1.3  Sequence analysis on HspA Cys residues 
A statistical survey of cysteine distribution in GroES proteins was carried out using the 
available sequences in the non redundant database RefSeq (release of February, 2007). 
Following the selection criteria defined in the Method section, and excluding HpHspA and its 
homologues, we identified 306 GroES sequences. displaying a Cys frequency of 0.05% 
(13/30165). Notably, only 13 out of them contain Cys residue (a list is available in the 
supplementary material). Its frequency across GroES proteins is ~ 0.1% revealing that 
cysteine is the less represented amino acid within the selected sequence subset (see table 
3.1). As a result, it can be deduced that Cys is not an essential residue for the function of 
GroES chaperonins. With this data at hand, the high Cys content (6/118) requires Hp ( and 
HELAC) HspA play additional and still unknown roles, peculiar of GroES like proteins from 
bacteria that attach the gastric mucosa.  
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Table 3.1: The table reports the frequency (%) for each amino acid residue analyzed. In red is reported the less 
represented amino acid, as cysteine, while in blue are reported the most represented amino acids 
 
3.1.4 Assessment of the oxidation state of HspA Cys residues 
The oxidation state of the cysteines occurring in HspA and in its mutants was assessed by 
determination of the accurate molecular mass of the proteins by electrospray mass 
spectrometry (ES/MS), following a procedure previously developed [Amoresano A. and Pucci 
P., 2003]. Aliquots of the HspA samples were directly analysed by ES/MS producing the 
spectra shown in figure 3.9.  Wt-HspA exhibited a molecular mass of 12984.0 0.8 Da, about 
6 Da lower than expected for the fully reduced protein (theoretical mass value 12990.9), thus 
suggesting that the 6 Cys residues were involved in 3 disulphide bridges. Accordingly, the 
molecular mass of HspA shifted to 12989.9 0.4 Da following reduction with DTT, exhibiting 
the expected increase of about 6 Da, whereas no difference in the mass value was observed 
following direct alkylation of the protein with an excess of IAM, confirming the absence of free 
Cys residues (data not shown). Finally, when the wt protein was first reduced with DTT and 
then carboxyamidomethylated with IAM, the corresponding ES/MS spectrum exhibited a 
molecular mass of 13331.5 0.8, as shown in figure 3.9(B), with an increase of 340.6 Da, 
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corresponding to the alkylation of 6 Cys residues. Similar experiments were also carried out 
on the HspA mutants. Figure 3.9(C) shows the ESMS spectrum of the Cys94Ala/Cys111Ala 
double mutant exhibiting a molecular mass of 12921.0 0.4 Da, about 4 Da lower than 
expected for the fully reduced protein, suggesting the occurrence of two S-S bridges. This 
result was confirmed by the reduction and reduction/alkylation experiments analogous to 
those described above for wt-HspA indicating that very likely the two mutated cystein 
residues, Cys94 and Cys111, were joined by a disulphide bond in the wt-HspA molecule. 
Finally, the ESMS analysis of the Cys94Ala single mutant yielded a mass value of 
25903.8 1.0 Da, as shown in figure 3.9(D), corresponding to a dimeric species stabilised by 
an intermolecular disulphide bridge very likely involving the free Cys111 residue of each HspA 
molecule. 
3.1.5 Disulphide bridge pattern 
Assignment of the disulphide bridges pattern in both wt-HspA and the double mutant was 
accomplished according to the well established mass mapping strategy described in 2.5.6 
section. Wt-HspA was digested with trypsin at pH 6.0 to avoid scrambling of S-S bridges and 
the resulting peptide mixture was directly analysed by MALDI-MS. Figure 3.9(A) shows the 
high mass region of the resulting MALDI spectrum recorded in linear mode where a series of 
mass signals was attributed to S-S bridged peptides. The peaks at m/z 4234.8 and 3969.6 
were interpreted as arising from the peptide 78-103, originated by aspecific cleavage at 
Tyr77, joined to the fragments 107-118 and 107-116, respectively by two disulphide bridge 
involving the four Cys residues at positions 94, 95, 111 and 112. Both mass signals were 
accompanied by satellite peaks at about 335 Da higher (m/z 4571.8 and 4304.5) 
corresponding to the same peptide 78-103 linked to the fragments 104-118 and 104-116 
respectively via the same two S-S bridges. Finally the mass signals at m/z 3891.1 and 3626.3 
were attributed to the peptide 81-103 bridged to the fragments 107-118 and 107-116 by two 
disulphides involving the above mentioned four cysteines (see Table 3.2).  All these signals 
disappeared following incubation with DTT. The mass spectral investigation of wt-HspA 
provided the overall scheme of cysteine pairings with Cys94, 95, 111 and 112 originating a 
network of two disulphide bridges and Cys51 and Cys53 forming the third S-S bridge. This 
interpretation was supported by the weak mass signal at m/z 2404.3 observed in the MALDI 
reflectron spectrum and was further confirmed by the double mutant analysis (see below). 
This peak occurred 2 Da lower than the peptide 42-64, suggesting the presence of an 
intermolecular disulphide bridge joining Cys51 and Cys53. 
The correct pairings of the Cys residues in HspA was obtained by the MALDI mass spectral 
analysis of the tryptic digest of the C94A/C111A double mutant. As shown in figure 3.10, 
mutation of the two Cys residues seemed not to affect the C-terminal pattern of disulphide 
bridges. The mass signals at m/z 5344.7, 5053.7 (peptides 65-103 and 67-103 joined to 107-
116 respectively) and 3907.7, 3564.6 and 3322.4 (peptides 78-103, 81-103 and 83-103 linked 
to the fragment 107-116) essentially corresponded to the previously observed S-S bridged 
peptides. This strongly suggests that Cys94 and Cys111 are held together by a S-S bridge in 
wt-HspA. The C-terminal fragments are then still joined by the second disulphide bond 
involving Cys95 and Cys112. The third S-S bridge involving Cys51 and Cys53 was confirmed 
by the mass signal at m/z 964.5 (peptide 47-55 containing an intramolecular disulphide 
bridge) leading to the unambiguous assignment of the S-S bridge pattern in HspA. 
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Fig. 3.9: ESMS spectra. a)WT HspA; b) HspA carboxymethylated at position 51, 53, 94, 95, 111, 112, after 
reduction with DDT; c) C94A/C111A double mutant; d) dimeric C94A mutant. 
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Table 3.2: Table of peptides obtained from  trypsine digestion and involved in the S-S bonds formation. It is 
reported the observed Mass, as experimental result, and the theoretical Mass calculated with the software MS-
digest 
 
 
Fig. 3.10: Maldi spectra obtained from peptide mixtures following the mass mapping strategy  
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3.1.6 Role of S-S bonds 
 
As previously described, we found that, under non reducing conditions, HspA contains 3 
intramolecular disulfide bridges. The bonds involve either the GroES-like domain A (Cys51-
Cys53) or the nickel-binding domain B (Cys94–Cys111 and Cys95–Cys112). The latter 2 
bridges dramatically affect the topology of the C-terminal domain generating a very unusual 
“lasso-like” structure: a small rigid ring of 16 atoms built up from the two disulfide bridges and 
a large flexible ring formed by 18 residues of the B domain. This large closed loop, embodies 
5 His residues leaving out of the ring the neighbouring 3 C-terminal His (Fig. 3.11). It is 
tempting to speculate that this lasso-like structure would be ideal to position the hystidine side 
chain in conformation suitable to bind nickel ions. Previous data showed that, under non-
reducing conditions, MBP-fused HspA binds 2 Ni(II)/molecule with an apparent Kd of 1.8 µM, 
whereas free HspA binds only 0.6 Ni(II)/molecule with a lower Kd (0.6 µM). We surmise that 
the difference in stechiometry and equilibrium constants may be related to the Cys state, as 
the MBP may protect the small HspA chain from Cys reduction/oxidation.  
HspA occurs at approximately 50% either in the soluble protein fraction in the structure bound 
protein fraction, suggesting that the subcellular localization might depend on the environment 
conditions. Along this line, our findings suggest that HspA may switch from an oxidised to a 
reduced state depending on redox control of the environment. This holds particularly for the 
cell surface, where the protein is embedded in an oxidizing environment and then contains 3 
S-S bridges; whereas the cytoplasmatic protein may exhibit a diverse Cys redox-state (Fig. 
3.12). In conclusion, our results suggest that two of the disulphide bridges, located in the B 
domain force the C-term domain to adopt a unique closed loop structure built-up from vicinal 
disulfide bridges which is relevant to the Ni dependent functioning of HspA in H. pylori. This 
structural determinant would be optimal for binding up to 2 Ni ions as suggested by the 
different redox environments that the protein experiences inside and outside the bacterial cell 
[Loguercio S., et al. 2008]. 
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Fig. 3.11: Space filled representation of the A domain of HspA obtained by homology modelling. B domain has 
been built by COOT and  represented as a green coil; S-S bonds are showed in blue. 
 
 
Fig. 3.12: Schematic representation of B-domain in two different states: reduced and oxidized. In the oxidized 
state, two of the disulphide bridges, located in the B domain, force the C-term domain to adopt a unique closed 
loop structure. 
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3.2 Expression and purification of Type III PanK, HpCoaX 
The CoaX protein from H. pylori was prepared by cloning into a pPROEX-HTc expression 
vector, according to the methods reported in 2.4.3.2 section. The vector was transformed into 
E. coli BL21DE3pLysS strain. The protein of interest was overexpressed and then the cell 
extract containing recombinant Hp0862 was loaded onto a His-trap affinity column pre-
equilibrated with buffer A for the first purification step (Fig. 3.13 A).  Proteins fractions were 
eluted applying an Imidazole gradient, with the elution buffer B. The eluted fractions were 
resolved by SDS-PAGE (Fig. 3.13 B). Protein fractions were pooled, digested with TEV 
protease and finally applied to a gel filtration column for the following purification steps.  The 
purity and the homogeneity of HpCoaX was firstly verified by SDS-PAGE analysis and after 
by mass spectrometry. 
 
 
 
Fig. 3.13(A): Chromatogram from purification of H. pylori CoaX using Ni affinity chromatography. Hp0862 is 
detected in fractions 63 to 68, These fractions represent the 6xHis-Hp0862 peak marked by the arrow in the 
chromatogram. The Y-axis indicates the absorbance given in mAU (milli absorbance unit). The X-axis indicates 
the elution volume in ml. 
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Fig. 3.13(B): SDS-PAGE analysis. the fractions. The brace indicates the fractions eluted from His-Trap column, 
containing the recombinant Hp_0862, corresponding to the size marker of 25kDa.  
In order to obtain the pure HpCoax without its artificial tail, we have utilized the best 
conditions for the TEV cleavage, after a long protocol’s screening. Digestion with TEV 
protease was performed at 4°C overnight, in the presence of DTT, directly setting the sample 
into the appropriate membrane for dialysis (Fig. 3.14). After 16h we can observe from the gel, 
that is present a lower molecular weight band which confirms that the Tag-cleavage was 
performed successfully.  After this step, we have re-loaded Hp_0862 cleaved on His trap 
column and concentrated the sample for the following analysis.  
 
Fig. 3.14: Histrap profile and SDS-PAGE analysis to verify the correct digestion of Hp_0862.   
       After 16h the band on the gel, is lower than the band at the time 0 (before the cleavage) 
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3.2.1 Sequence analysis of type III PanK, HpCoaX 
A comparison among various Pank III sequences has revealed that Hp_0862 contains a high 
amount of Cys residues as showed in figure 3.15 (3,6%). The Cys presence within a 
sequence can interfere with the protein stability. 
 
 
 
Fig. 3.15: Amino acid sequence of Hp_0862. 8 cysteines are highlighted in red. 
 
Indeed during the purification steps, we have observed a different behavior of the HpCoaX 
samples, depending on temperature of the storage and also on the presence of a reducing 
agent. We can observe the possible presence of non native S-S bonds which interfere with 
the protein stability (Fig. 3.16). 
           
Fig. 3.16: Protein sample is stored at various temperature: 4°C. -20°C and -80°C. In  the absence of the 
reducing agent, SDS-PAGE shows  multiple bands pattern as indicate by the black arrow on the right.  
 
To obtain a stable protein sample, it was necessary the treatment with a reducing agents (use 
of 2-3 mM DTT) during each purification steps. To limit the aerobic oxidation, both of DTT and 
MPARQSFTDLKNLVLCDIGNTRIHFAQNYQLFSSAKEDLKRLGIQKEIFYISVNEENEK
ALLNCYPNAKNIAGFFHLETDYVGLGIDRQMACLAVNNGVVVDAGSAITIDLIKEGKHL
GGCILPGLAQYIHAYKKSAKILEQPFKALDSLEVLPKSTRDAVNYGMVLSVIACIQHLA
KNQKIYLCGGDAKYLSAFLPHSVCKERLVFDGMEIALKKAGILECK
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of Cys residues present in the sample,  the protein  preparation and the final step of storage 
were carried out under N2 atmosphere. This specific wariness is important to control the 
aggregates formation and also to obtain a stable sample, in particular to investigate on the 
protein oligomerization state and to carry out crystallization trials. 
 
3.2.1.2  Free SH- groups analysis 
To confirm that the height cysteines present in the amino acid sequence of HpCoaX were not 
involved into any intra-molecular disulphide bridge, we have carried out a 4-Vinyl-pyridine 
assay. Hp_0862 was denatured and then alkylated with the 4-VP. This step is important for 
the incorporation of 4-VP molecule into the protein. To visualize the molecular mass increase 
and so to determine the effectively linkage between the Cys residues and the 4-VP, the 
samples were submitted to a LC-MS analysis. Looking at the Figure 3.17 we can observe the 
real increase of molecular mass: 24.971 Da+ [105x8]. 
 
 
Fig. 3.17: LC-MS spectra of Hp0862 
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3.2.3 Biochemical characterization of Type III PanK,  HpCoaX 
Many biochemical and biophysical methods can be used to characterize the oligomerization 
state of proteins. Accurate information about the quaternary structure of HpCoaX protein was 
obtained combining molecular exclusion chromatography with light scattering analysis. The 
purified HP_0862 was analyzed by gel filtration chromatography and dynamic light scattering 
to investigate its state of oligomerization. The Gel filtration was performed using a 
Superdex_200 column, pre-equilibrated in the buffer containing 50 mM Tris pH 8.0, 200 mM 
NaCl and 2 mM DTT, and calibrated with the reference standards at Ve known. The PanKIII 
from H. pylori reports a Ve  of 15.2 mL/min, which corresponds to a molecular weight of about 
50 kDa, comparable to that expected for a dimeric organization (Fig. 3.18). This result is in 
according to the homology prediction reported for the other PanK enzymes which function as 
a dimer for their catalysis. 
 
 
Fig. 3.18: Gel filtration profile of Hp0862 obtained by size exclusion chromatography. Results show that HP0862 
exists as a homodimer, as predicted by its homology with the other PanK III bacterial proteins. 
 
To confirm this data the purified protein was also submitted to an accurate analysis of DLS 
(Dynamic Light Scattering), using the same column Superdex_200 and the same running 
buffer. The figure 3.19 shows a SEC-MALS profile. The polydispersity, expressed as Mw/Mn, 
is about of 1.001(with an error of 4%). The Molar mass moments (g/mol) is Mn 4.790e+4 
(error 3%) and Mp is 4.820e+4(error 2%). 
The protein identity was assessed by liquid chromatography and mass spectrometry: data 
give a 24.971Da molecular mass of the recombinant HpCoaX, which is in good agreement 
with the theoretical molecular mass calculated according to the amino acid sequence. 
Ve= 15,2 ml/minVe= 15,2 ml/min
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Fig. 3.19(A): SEC-time course of Hp0862 sample. The black arrow shows the deconvoluted peak corresponding 
to protein area signals. 
 
 
 
 
Fig. 3.19(B): SEC-MALS profile obtained from derivation calculus. Molar mass plot versus time. 
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3.2.4 Crystallization experiment 
The crystallization conditions were performed as described in 2.5.9 section. Several crystal 
forms were obtained only at 4°C, not at 20°C, confirming the intrinsic protein difficulty  to 
remain in a stable form. Only diffraction data at low resolution were obtained from these 
crystals (about 5 Å). 
In order to improve the crystal quality we have also carried out the crystallization  experiment 
in presence of Pan and AMPNP. Unfortunately, also these crystals diffracted a 5.0 Å of 
resolution, not enough to solve the structure  
 
3.3 H. pylori PanK III, a new target for antimicrobical agents 
There are several functional advantages that may be conferred by oligomerization and that 
may have been selected for through evolution. The study of protein oligomerization can 
provide insights into the early protein environment and the evolution of modern proteins. So, 
the advises from the HpCoaX oligomerization state represent a good starting point for future 
investigations among this PanK enzyme. Belonging to the Type III class, HpCoax posses 
indeed specific features in the mode of binding the substrate and also exhibits particular 
characteristics in its catalytic action. The Type III is drastically distinct from the Type II class in 
the substrate binding and dimer formation modes; although the SaCoaA (Type II) and 
PaCoaA (Type III)  monomers have very similar structures, they each contain a loop region 
that is absent from the other enzyme, which results in their assembly into dimers with 
distinctly different architectures. Although both loops contribute to the monomer-monomer 
interface, they do so in different ways. Due to the different structures of the insertion elements 
which comprise a large portion of the dimer interface in both PanK-II and PanK-III, the relative 
arrangement of two monomers in the dimer are very different for the two enzymes, resulting in 
distinct and mutually exclusive Pan-binding pockets. [Hong B.S., et al. 2006], [Yang K., et al. 
2009]. 
The alarming rise of antibiotics resistance among key bacterial pathogens is stimulating an 
urgent need to discover novel antibacterial agents acting on new drug targets. Fortunately, 
the accomplishment of H. pylori genome-sequencing project [Tomb G.F., et al . 1997] has 
heralded a new era for antibacterial chemotherapy against the pathogenic bacterium. At the 
same time, comparison of bacterial target genes with human genes will also be necessary 
because, to avoid adverse effects, a good antimicrobial drug target should have no homolog 
in mammalian cells. Clearly, alternative strategies are needed to develop new types of 
specific  H. pylori inhibitors that target PanK enzymes in general, and the type III PanKs that 
occur in a wide range of pathogenic bacteria in particular. I hope that further research into 
HpCoaX protein will be able to answer some of these burning questions. 
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Abstract Helicobacter pylori produces a heat shock protein A
(HspA) that is unique to this bacteria. While the first 91 residues
(domain A) of the protein are similar to GroES, the last 26 (do-
main B) are unique to HspA. Domain B contains eight histidines
and four cysteines and was suggested to bind nickel. We have
produced HspA and two mutants: Cys94Ala and Cys94Ala/
Cys111Ala and identified the disulfide bridge pattern of the pro-
tein. We found that the cysteines are engaged in three disulfide
bonds: Cys51/Cys53, Cys94/Cys111 and Cys95/Cys112 that re-
sult in a unique closed loop structure for the domain B.
Ó 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Small heat shock protein; Chaperonin GroES;
Nickel binding protein; Mass spectrometry;Helicobacter pylori
1. Introduction
Helicobacter pylori is a gram negative bacteria that colonise
the human stomach. It is present in more than half of the
worldÕs population and causes major diseases such as gastritis,
peptic ulcers and stomach cancer [1]. To colonise this highly
acidic niche, this neutrophile bacterium has developed peculiar
strategies. Among them the production of the urease is the
most important one [2,3]. Urease is a nickel-dependent enzyme
that hydrolyses urea to produce ammonia, which allows the
bacteria to survive at low pH [4,5]. The activity of urease
strongly depends on the availability of nickel ions [6]. Other
proteins such as Hpn, Hpn-like, NixA, Frpb4 and a heat shock
protein, namely HspA, have been demonstrated to bind the
metal playing the role of importing, providing or sequestering
nickel ions [7–9].
Heat shock proteins (Hsp) synthesis is stimulated in re-
sponse to abnormal environmental conditions like such as heat
shock, oxidative stress, and also exposure to heavy metals. The
proteins are found in all domains of life where they actually act
as molecular chaperons [10]. A subgroup, referred as to small
Hsp, shares common features such as small molecular mass
(10–30 kDa).
The small heat shock protein A (HspA) from H. pylori is an
essential protein with a double localization. Unexpectedly this
cytoplasmic protein, has been localised also on the bacterium
surface. Whether this protein is released through a specific
secretion mechanism or a programmed bacterium autolysis is
an interesting matter of debate [11,12].
Owing to its external localization, HspA presents strong
antigenic properties [13–15]. A protective immunity from the
infection was induced in mice after immunization with HspA.
The protein has been then considered appealing as a vaccine
component [13].
HspA consists of 118 amino-acids divided in two domains;
the A domain (1–91) and the B domain (92–118). The domain
A of the protein shares sequence similarity to the GroES se-
quence [13]. The domain B of HspA is unique to H. pylori
and Helicobacter acinonuchis and contains eight histidines
and four cysteines.
This unusual sequence plays a role in Ni uptake and release
[9,13,15,16] to assist nickel homeostasis in vivo. The B domain
does exhibit high affinity for nickel ions with dissociation con-
stants of 1.8 lM [15] and 1.1 lM [16]. In vitro, the binding to
nickel is pH dependent, being the nickel released at low pH
(pH 1/2 = 3.8) and was demonstrated by several complemen-
tary methods such as dialysis equilibrium, UV–Vis spectros-
copy, ICP-MS mass [15,16].
Cys is the less represented amino-acid in the GroES protein
family, because it does not serve for the co-chaperonin func-
tion. Vice versa, no substitution affects the His/Cys residues
of HspA sequence even though several substitutions occur
among clinical isolates, suggesting that these amino-acids
are specifically involved in nickel homeostasis [9,15]. There-
fore, the role played by the B domain should be mediated
by a high number of cysteines with capacity of different redox
state.
To get insight into Cys role, we have produced the
wild-type HspA as well as two mutants: Cys94Ala and
Cys94Ala/Cys111Ala. By combining biochemical methods
with mass spectrometry, we have determined the Cys oxida-
tion state, assigned the disulfide bridge pattern and pro-
vided evidence for a unique lasso-like structure of the B
domain in HspA.Abbreviations: HspA, heat shock protein A; IAM, iodoacetamide;
DTT, dithiothreitol
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2. Materials and methods
2.1. Expression and purification of HspA from H. pylori
The wild-type HspA was expressed and purified using the vector
pILL948 described in [15]. Single (C94A) and double (C94A/C111A)
HspA mutants were constructed using the QuickChange site directed
mutagenesis protocol (Stratagene). E. coli BL21(DE3)pLysS, carrying
the expression vector, was grown in LB medium at 37 °C, and the
expression of the recombinant product was induced by 1 mM isopro-
pyl-D-thiogalactopyranoside (IPTG). The cells were harvested by cen-
trifugation, resuspended in lysis buffer A (20 mM Na2HPO4 pH 7.4,
500 mM NaCl and 1 mMMgCl2) and disrupted by sonication. The
soluble fraction was isolated from the cell debris by centrifugation
and applied to a HiTrap HP column (Amersham Biosciences) charged
with 100 mM NiSO4 and equilibrated with buffer A. The protein was
eluted from the column using a gradient of 0–100% buffer B (buffer
A and 500 mM imidazole), and further purified by size exclusion chro-
matography (Superdex 200 (10/30); Amersham Biosciences) in a buffer
(20 mM Tris pH 7.4, 200 mM NaCl).The purity and homogeneity was
first tested by SDS–PAGE and then by mass spectrometry.
2.2. Mass spectrometry measurements
Reduction with DDT and alkylation with IAM were carried out
according to [17]. HPLC-desalted samples of wt-HspA and mutants
were directly analyzed by ES/MS using a Quattro Micro triple quadru-
pole mass spectrometer (Waters). Wt-HspA and both mutants samples
were digested with trypsin in 50 mM ammonium acetate, pH 6.0 at
37 °C overnight, and the mixtures of tryptic peptides were directly ana-
lyzed by MALDI mass spectrometry using a Voyager DE PRO instru-
ment (Applied Biosystem) operating both in linear and reflectron
mode.
3. Results and discussion
3.1. Assessment of the oxidation state of HspA Cys residues
The oxidation state of the cysteines occurring in HspA and
in its mutants was assessed by determination of the accurate
molecular mass of the proteins by electrospray mass spectrom-
etry (ESMS), following a procedure previously developed [17].
Aliquots of the wt-HspA and both mutants samples were di-
rectly analyzed by ESMS producing the spectra shown in
Fig. 1. Wt-HspA exhibited a molecular mass of 12984.0 ±
0.8 Da, about 6 Da lower than expected for the fully reduced
protein (theoretical mass value 12990.9), thus suggesting that
the six Cys residues were involved in three disulfide bridges.
Accordingly, the molecular mass of HspA shifted to
12989.9 ± 0.4 Da following reduction with DTT, exhibiting
the expected increase of about 6 Da, whereas no difference in
the mass value was observed following direct alkylation of
MW
12984.0+0.8
MW
13331.5+0.8
A B
DC
MW
25903.8+1.0
MW
12921.0+0.4
HspA
wild type
HspA cam
HspA double
mutant
HspA single
mutant
Fig. 1. ESMS spectra. (A) Wt-HspA; (B) HspA carboxymethylated at position 51, 53, 94, 95, 111, 112, after reduction with DDT; (C) C94A/C111A
double mutant; (D) dimeric C94A mutant.
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the protein with an excess of IAM, confirming the absence of
free Cys residues (data not shown). It is worth noting that,
after reduction, disulfides quickly reform in air. Finally, when
the wt protein was first reduced with DTT and then carboxy-
amidomethylated with IAM, the corresponding ESMS spec-
trum exhibited a molecular mass of 13331.5 ± 0.8, as shown
in Fig. 1B, with an increase of 340.6 Da, corresponding to
the alkylation of six Cys residues.
Similar experiments were also carried out on the HspA mu-
tants. Fig. 1C shows the ESMS spectrum of the Cys94Ala/Cy-
s111Ala double mutant exhibiting a molecular mass of
12921.0 ± 0.4 Da, about 4 Da lower than expected for the fully
reduced protein, suggesting the occurrence of two S–S bridges.
This result was confirmed by the reduction and reduction/
alkylation experiments analogous to those described above
for wt-HspA, indicating that the two mutated cystein residues,
Cys94 and Cys111, were joined by a disulfide bond in the wt-
HspA molecule. Finally, the ESMS analysis of the Cys94Ala
single mutant yielded a mass value of 25903.8 ± 1.0 Da, as
shown in Fig. 1D, corresponding to a dimeric species stabilised
by an intermolecular disulfide bridge likely involving the free
Cys111 residue of each HspA molecule.
3.2. Disulfide bridge pattern
Assignment of the disulfide bridges pattern in both wt-HspA
and the double mutant was accomplished according to the well
established mass mapping strategy [17–20]. Wt-HspA was di-
gested with trypsin at pH 6.0 to avoid scrambling of S–S
bridges and the resulting peptide mixture was directly analyzed
by MALDI-MS. Fig. 2A shows the high mass region of the
resulting MALDI spectrum recorded in linear mode where a
series of mass signals was attributed to S–S bridged peptides.
The peaks at m/z 4234.8 and 3969.6 were interpreted as arising
from the peptide 78–103, originated by aspecific cleavage at
Tyr77, joined to the fragments 107–118 and 107–116, respec-
tively by two disulfide bridges involving the four Cys residues
at positions 94, 95, 111 and 112. Both mass signals were
accompanied by satellite peaks at about 335 Da higher (m/z
4571.8 and 4304.5) corresponding to the same peptide 78–
103 linked to the fragments 104–118 and 104–116, respectively
via the same two S–S bridges. Finally the mass signals at m/z
3891.1 and 3626.3 were attributed to the peptide 81–103
bridged to the fragments 107–118 and 107–116 by two disul-
fides involving the above mentioned four cysteines. All these
signals disappeared following incubation with DTT.
The mass spectral investigation of wt-HspA provided the
overall scheme of cysteine pairings with Cys94, 95, 111 and
112 originating a network of two disulfide bridges and Cys51
and Cys53 forming the third S–S bridge. This interpretation
was supported by the weak mass signal at m/z 2404.3 observed
in the MALDI reflectron spectrum and was further confirmed
by the double mutant analysis (see below). This peak occurred
2 Da lower than the peptide 42–64, suggesting the presence of
an intermolecular disulfide bridge joining Cys51 and Cys53.
The correct pairings of the Cys residues in HspA was
obtained by the MALDI mass spectral analysis of the tryptic
digest of the C94A/C111A double mutant. As shown in
Fig. 2B, mutation of the two Cys residues seemed not to affect
the C-terminal pattern of disulfide bridges. The mass signals at
m/z 5344.7, 5053.7 (peptides 65–103 and 67–103 joined to 107–
116, respectively) and 3907.7, 3564.6 and 3322.4 (peptides
78–103, 81–103 and 83–103 linked to the fragment 107–116)
essentially corresponded to the previously observed S–S
bridged peptides. This strongly suggests that Cys94 and
Fig. 2. MALDI-MS spectra after tryptic digestion of: (A) Wt-HspA; (B) C94A/C111A double mutant.
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Cys111 are held together by an S–S bridge in wt-HspA. The C-
terminal fragments are then still joined by the second disulfide
bond involving Cys95 and Cys112. The third S–S bridge
involving Cys51 and Cys53 was confirmed by the mass signal
at m/z 964.5 (peptide 47–55 containing an intramolecular disul-
fide bridge) leading to the unambiguous assignment of the S–S
bridge pattern in HspA.
4. Conclusion
In this study, we found that HspA contains three intramo-
lecular disulfide bridges. The bonds involve either the
GroES-like domain A (Cys51–Cys53) or the nickel-binding
domain B (Cys94–Cys111 and Cys95–Cys112). In the latter
domain, the small 4-Cys ring we identified constitutes a strong
and very rare structural determinant, being observed only in
the conotoxin, a short peptide (pdb code 1wct) [21]. Indeed,
in HspA the two consecutive S–S bridges form a rigid knot
that dramatically affects the topology of the C-terminal do-
main generating a ‘‘lasso-like’’ structure, here described for
the first time (Fig. 3). A large and flexible ring, formed by 18
residues, embodies five His residues leaving out of the lasso
the neighboring three C-term His. This lasso-like structure
would be ideal to position the ligand side chains in conforma-
tion suitable to bind up to two nickel ions [15,16]. The Ni bind-
ing role may be played by HspA either through intracellular or
extracellular Ni sequestration, as the protein was also found in
association with the outer membrane and as a subcellular
material [11,12]. Along this line, it is tempting to speculate that
HspA might switch from an oxidised to a reduced state
depending on the environment. This holds for the cell surface,
where the protein is embedded in an oxidizing environment
and then possesses the S–S bridges; whereas, in cytoplasm,
the disulfide bridges may exhibit a diverse stability, depending
on the conditions (pH and Ni depletion or overload).
In conclusion, being the cysteines strongly conserved in dif-
ferent strains they may have the role to assist the Ni binding/
release. Then the unique lasso-like structure, built-up from vic-
inal disulfide bridges is relevant to the Ni dependent function-
ing of HspA in H. pylori.
Acknowledgments: We are indebted to Prof. A. Labigne and Dr. H.
De Reuse for communicating some of their results on HspA prior
to publication and for providing us with the vector pILL948. We
thank Ulrike Kapp for technical assistance with the purification of
HspA. This work was supported by FIRB RBRN07BMCT and the
ESRF.
References
[1] Covacci, A., Telford, J.L., del Giudice, G., Parsonnet, J. and
Rappuoli, R. (1999) Helicobacter pylori virulence and genetic
geography. Science 284, 1328–1333.
[2] Eaton, K.A., Brooks, C.L., Morgan, D.R. and Krakowka, S.
(1991) Essential role of urease in pathogenesis of gastritis induced
by Helicobacter pylori in gnotobiotic piglets. Infect. Immunol. 59,
2470–2475.
[3] Stingl, K. and De Reuse, H. (2005) Stayng alive overdosed: how
does Helicobater pylori control urease activity? Int. J. Med.
Microbiol. 295, 307–315.
[4] Bauerfeind, P., Garner, R., Dunn, B.E. and Mobley, H.L. (1997)
Synthesis and activity ofHelicobacter pylori urease and catalase at
low pH. Gut 40, 25–30.
[5] Stingl, K., Altendorf, K. and Bakker, E.P. (2002) Acid survival of
Helicobacter pylori: how does urease activity trigger cytoplasmic
pH homeostasis? Trends Microbiol. 10, 70–74.
[6] van Vliet, A.H., Kuipers, E.J., Stoof, J., Poppelaars, S.W. and
Kusters, J.G. (2004) Acid-responsive gene induction of
ammonia-producing enzymes in Helicobacter pylori is mediated
via a metal-responsive repressor cascade. Infect. Immunol. 72,
766–773.
[7] Bury-Mone´, S., Thiberge, J.M., Contreras, M., Maitournam, A.,
Labigne, A. and De Reuse, H. (2004) Responsiveness to acidity
via metal ion regulators mediates virulence in the gastric pathogen
Helicobacter pylori. Mol. Microbiol. 53, 623–638.
[8] Schauer, K., Gouget, B., Carriere, M., Labigne, A. and de Reuse,
H. (2007) Novel nickel transport mechanism across the bacterial
outer membrane energized by the TonB/ExbB/ExbD machinery.
Mol. Microbiol. 63, 1054–1068.
[9] Sun, X., Ge, R., Chiu, J.F., Sun, H. and He, Q.Y. (2008)
Identification of proteins related to nickel homeostasis in Helic-
obater pylori by immobilized metal affinity chromatography and
two-dimensional gel electrophoresis. Met. Based Drugs 2008,
289490.
[10] Horwich, A.L., Fenton, W.A., Chapman, E. and Farr, G.W.
(2007) Two families of chaperonin: physiology and mechanism.
Annu. Rev. Cell Dev. Biol. 23, 115–145.
[11] Vanet, A. and Labigne, A. (1998) Evidence for specific secretion
rather than autolysis in the release of some Helicobacter pylori
proteins. Infect. Immunol. 66, 1023–1027.
[12] Phadnis, S.H., Parlow, M.H., Levy, M., Ilver, D., Caulkins, C.M.,
Connors, J.B. and Dunn, B.E. (1996) Surface localization of
Helicobacter pylori urease and a heat shock protein homolog
requires bacterial autolysis. Infect. Immunol. 64, 905–912.
[13] Suerbaum, S., Thiberge, J.M., Kansau, I., Ferrero, R.L. and
Labigne, A. (1994) Helicobacter pylori hspA-hspB heat-shock
gene cluster: nucleotide sequence, expression, putative function
and immunogenicity. Mol. Microbiol. 14, 959–974.
[14] Ferrero, R.L., Thiberge, J.M., Kansau, I., Wuscher, N., Huerre,
M. and Labigne, A. (1995) The GroES homolog of Helicobacter
pylori confers protective immunity against mucosal infection in
mice. Proc. Natl. Acad. Sci. USA 92, 6499–6503.
[15] Kansau, I., Guillain, F., Thiberge, J.M. and Labigne, A. (1996)
Nickel binding and immunological properties of the C-terminal
domain of the Helicobacter pylori GroES homologue (HspA).
Mol. Microbiol. 22, 1013–1023.
[16] Cun, S., Li, H., Ge, R., Lin, M.C. and Sun, H. (2008) A histidine-
rich and cysteine-rich metal-binding domain at the C terminus of
heat shock protein A from Helicobacter pylori: implication for
nickel homeostatsis and bismuth susceptibility. J. Biol. Chem.
283, 15142–15151.
[17] Amoresano, A., Pucci, P., Duro, G., Colombo, P., Costa, M.A.,
Izzo, V., Lamba, D. and Geraci, D. (2003) Assignment of
disulphide bridges in Par j 20101, a major allergen of Parietaria
judaica pollen. Biol. Chem. 384, 1165–1172.
[18] Amoresano, A., Orru, S., Siciliano, R.A., De Luca, E., Napole-
oni, R., Sirna, A. and Pucci, P. (2001) Assignment of the complete
Fig. 3. Model of domain B (92-GSCCHTGNHDHKHAKE-
HEACCHDHKKH-118) in HspA. The disulfide bridge pattern
generating the lasso-like structure is indicated in red (Cys94-Cys111
and Cys95-Cys112). The side chains of cysteines and histidines are
displayed in sticks. Coordinates were obtained by manual building in
COOT [22].
3540 S. Loguercio et al. / FEBS Letters 582 (2008) 3537–3541
disulphide bridge pattern in the human recombinant follitropin
beta-chain. Biol. Chem. 382, 961–968.
[19] Galliano, M., Minchiotti, L., Campagnoli, M., Sala, A., Visai, L.,
Amoresano, A., Pucci, P., Casbarra, A., Cauci, M., Perduca, M.
and Monaco, HL. (2003) Structural and biochemical character-
ization of a new type of lectin isolated from carp eggs. Biochem. J.
376, 433–440.
[20] Morris, H.R. and Pucci, P. (1985) A new method for rapid
assignment of S–S bridges in proteins. Biochem. Biophys. Res.
Commun. 126, 1122–1128.
[21] Rigby, A.C., Lucas-Meunier, E., Kalume, D.E., Czerwiec, E.,
Hambe, B., Dahlqvist, I., Fossier, P., Baux, G., Roepstorff, P.,
Baleja, J.D., Furie, B.C., Furie, B. and Stenflo, J. (1999) A
conotoxin from Conus textile with unusual posttranslational
modifications reduces presynaptic Ca2+ influx. Proc. Natl. Acad.
Sci. USA 96, 5758–5763.
[22] Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for
molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60,
2126–2132.
S. Loguercio et al. / FEBS Letters 582 (2008) 3537–3541 3541
